A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.
Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Gastrointestinal symptoms resulting from an absent or nonfunctioning pylorus.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
A symptom complex associated with CARCINOID TUMOR and characterized by attacks of severe flushing of the skin, diarrheal watery stools, bronchoconstriction, sudden drops in blood pressure, edema, and ascites. The carcinoid tumors are usually located in the gastrointestinal tract and metastasize to the liver. Symptoms are caused by tumor secretion of serotonin, prostaglandins, and other biologically active substances. Cardiac manifestations constitute CARCINOID HEART DISEASE. (Dorland, 27th ed; Stedman, 25th ed)
A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.
A process whereby bile is delivered from the gallbladder into the duodenum. The emptying is caused by both contraction of the gallbladder and relaxation of the sphincter mechanism at the choledochal terminus.
Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin.
The presence of chyle in the thoracic cavity. (Dorland, 27th ed)
Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition.
The condition of accelerated and excessive GROWTH in children or adolescents who are exposed to excess HUMAN GROWTH HORMONE before the closure of EPIPHYSES. It is usually caused by somatotroph hyperplasia or a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. These patients are of abnormally tall stature, more than 3 standard deviations above normal mean height for age.
Abnormal passage communicating with the PANCREAS.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Presence of milky lymph (CHYLE) in the PERITONEAL CAVITY, with or without infection.
Dilatation of the intestinal lymphatic system usually caused by an obstruction in the intestinal wall. It may be congenital or acquired and is characterized by DIARRHEA; HYPOPROTEINEMIA; peripheral and/or abdominal EDEMA; and PROTEIN-LOSING ENTEROPATHIES.
Acquired degenerative dilation or expansion (ectasia) of normal BLOOD VESSELS, often associated with aging. They are isolated, tortuous, thin-walled vessels and sources of bleeding. They occur most often in mucosal capillaries of the GASTROINTESTINAL TRACT leading to GASTROINTESTINAL HEMORRHAGE and ANEMIA.
A benign epithelial tumor with a glandular organization.
A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Cardiac manifestation of gastrointestinal CARCINOID TUMOR that metastasizes to the liver. Substances secreted by the tumor cells, including SEROTONIN, promote fibrous plaque formation in ENDOCARDIUM and its underlying layers. These deposits cause distortion of the TRICUSPID VALVE and the PULMONARY VALVE eventually leading to STENOSIS and valve regurgitation.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
Messages between computer users via COMPUTER COMMUNICATION NETWORKS. This feature duplicates most of the features of paper mail, such as forwarding, multiple copies, and attachments of images and other file types, but with a speed advantage. The term also refers to an individual message sent in this way.
Mechanical food dispensing machines.
The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.
The profession of writing. Also the identity of the writer as the creator of a literary production.
A publication issued at stated, more or less regular, intervals.
The functions and activities carried out by the U.S. Postal Service, foreign postal services, and private postal services such as Federal Express.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL.
Concretions of swallowed hair, fruit or vegetable fibers, or similar substances found in the alimentary canal.
Pathological development in the JEJUNUM region of the SMALL INTESTINE.
The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM.
Pathological development in the ILEUM including the ILEOCECAL VALVE.
Pathological processes consisting of the union of the opposing surfaces of a wound.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed)
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. (1/953)

Somatostatin and its analogs can inhibit growth in several cell types, in part by interfering with insulin-like growth factor-I (IGF-I) signaling. Our previous studies point to the importance of paracrine and autocrine IGF-I in the support of growth and survival of human multiple myeloma (MM) cell lines. In this report, we have investigated the potential role of a somatostatin analog, octreotide, in regulating growth and/or survival in MM. The results show that all MM cell lines express functional somatostatin receptors (sst). The MM cell lines express the subtypes sst2, sst3, and predominantly sst5 as determined by reverse-transcriptase polymerase chain reaction and fluorescence-activated cell sorter analysis. Octreotide inhibited the growth of both the interleukin-6 (IL-6)-dependent and the IL-6-independent MM cell lines. The effect is mainly cytostatic, resulting in 25% to 45% growth inhibition, and in three of eight of the MM cell lines a weak induction of apoptosis was recorded. Our results also show that octreotide may act as an inducer of apoptosis in primary B-B4(+) plasma cells isolated from bone marrow of MM patients. In conclusion, the results show a novel pathway for growth inhibition of MM cells: the activation of somatostatin receptor signaling.  (+info)

In vivo localization of [(111)In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. (2/953)

Adenoviral vectors, encoding genes for cell surface antigens or receptors, have been used to induce their high level expression on tumor cells in vitro and in vivo. These induced antigens and receptors can then be targeted with radiolabeled antibodies or peptides for potential radiotherapeutic applications. The purpose of this study was to determine a dosing schema of an adenoviral vector encoding the human somatostatin receptor subtype 2 (AdCMVhSSTr2) for achieving the highest tumor localization of [(111)In]-DTPA-D-Phe1-octreotide, which binds to this receptor, in a human ovarian cancer model as a prelude to future therapy studies. AdCMVhSSTr2 was produced and used to induce hSSTr2 on A427 human nonsmall cell lung cancer cells and on SKOV3.ipl human ovarian cancer cells in vitro, as demonstrated by competitive binding assays using [125I]-Tyr1-somatostatin and [(111)In]-DTPA-D-Phe1-octreotide. Mice bearing i.p. SKOV3.ip1 tumors administered 1 x 10(9) plaque-forming units of AdCMVhSSTr2 i.p. 5 days after tumor cell inoculation, followed by an i.p. injection of [(111)In]-DTPA-D-Phe1-octreotide 2 days later, showed a range of 15.3-60.4% median injected dose/gram (ID/g) in tumor at 4 h after injection compared with 3.5% ID/g when [125I]-Tyr1-somatostatin was administered and 0.3% ID/g when the negative control peptide [125I]-mIP-bombesin was administered. Mice administered a control adenoviral vector encoding the gastrin-releasing peptide receptor did not have tumor localization of [(111)In]-DTPA-D-Phe1-octreotide (<1.6% ID/g), demonstrating specificity of [(111)In]-DTPA-D-Phe1-octreotide for the AdCMVhSSTr2 induced tumor cells. In another set of experiments, the tumor localization of [(111)In]-DTPA-D-Phe1-octreotide was not different 1, 2, or 4 days after AdCMVhSSTr2 injection (31.8, 37.7, and 40.7% ID/g, respectively; P = 0.88), indicating that multiple injections of radiolabeled peptide can be administered with equivalent uptake over a 4-day period. [(111)In]-DTPA-D-Phe1-octreotide tumor localization in animals administered AdCMVhSSTr2 on consecutive days or 2 days apart was 22.4% ID/g and 53.2% ID/g, respectively (P = 0.009) when [(111)In]-DTPA-D-Phe1-octreotide was given 1 day after the second AdCMVhSSTr2 injection. There was no difference in [(111)In]-DTPA-D-Phe1-octreotide localization after a single AdCMVhSSTr2 injection (40.7% ID/g) or two injections of AdCMVhSSTr2 given 1 (45.9% ID/g) or 2 (53.2% ID/g) days apart, where [(111)In]-DTPA-D-Phe1-octreotide was given in each case 4 days after the first AdCMVhSSTr2 injection (P = 0.65). Therefore, two AdCMVhSSTr2 injections did not increase [(111)In]-DTPA-D-Phe1-octreotide tumor localization compared with one injection, which eliminates concerns about an immune response to a second dose of AdCMVhSSTr2. This will be the basis for a therapeutic protocol with multiple administrations of an octreotide analogue labeled with a therapeutic radioisotope.  (+info)

Kleine-Levin and Munchausen syndromes in a patient with recurrent acromegaly. (3/953)

Hypothalamic disease often affects the patients' personality and this also applies to pituitary tumors with suprasellar extension. We report on a patient with a 12-year history of recurrent acromegaly, treated with three transphenoidal operations, single field radiation therapy and bromocriptine/octreotide administration. During the course of follow-up she presented with self-inflicted anemia and Kleine-Levin syndrome (hypersomnia, hyperphagia and hypersexuality). Furthermore, she developed post-radiation necrosis within the right temporal lobe. Whether her neurological and personality disorders result - at least partially - from the acromegaly or the temporal lobe necrosis remains unclear.  (+info)

Primary hepatic carcinoid in a renal transplant patient. (4/953)

There seems to be a world-wide increase in the incidence of tumors among immunosuppressed patients. Of 1350 renal allografts transplanted in the past 23 years at the Department of Transplantation and Surgery, 56 cases were malignant tumors. The case of a 58-year-old female patient is reported, with disseminated primary carcinoid in the liver detected 86 days after renal transplantation. According to the literature only 39 patients with primary liver carcinoids have been reported until 1997, but this is the first where the carcinoid developed in an immunosuppressed patient. The rapid progression of the carcinoid could be associated with the immunosuppression.  (+info)

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. (5/953)

PURPOSE: Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily. A microencapsulated long-acting formulation (LAR) of octreotide acetate has been developed for once-monthly intramuscular dosing. PATIENTS AND METHODS: A randomized trial compared double-blinded octreotide LAR at 10, 20, and 30 mg every 4 weeks with open-label SC octreotide every 8 hours for the treatment of carcinoid syndrome. Seventy-nine patients controlled with treatment of SC octreotide 0.3 to 0.9 mg/d whose symptoms returned during a washout period and who returned for at least the week 20 evaluation constituted the efficacy-assessable population. RESULTS: Complete or partial treatment success was comparable in each of the four arms of the study (SC, 58.3%; 10 mg, 66.7%; 20 mg, 71.4%; 30 mg, 61.9%; P> or =.72 for all pairwise comparisons). Control of stool frequency was similar in all treatment groups. Flushing episodes were best controlled in the 20-mg LAR and SC groups; the 10-mg LAR treatment was least effective in the control of flushing. Treatment was well tolerated by patients in all four groups. CONCLUSION: Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.  (+info)

Exogenous cysteamine increases basal pancreatic exocrine secretion in the rat. (6/953)

To determine whether exocrine pancreatic secretion is regulated by endogenous somatostatin, somatostatin deficiency was induced by cysteamine. Rats were subcutaneously administered a single dose of cysteamine (30 mg/100 g body weight) 12 hr before experiment. Anesthetized rats were prepared with cannulation into bile duct, pancreatic duct, duodenum, and jugular vein and pancreatic juice was collected. For in vitro study, isolated pancreata of rats, pretreated with cysteamine, were perfused with an intraarterial infusion of Krebs-Henseleit solution (37 degrees C) at 1.2 mL/min, and pancreatic juice was collected in 15-min samples. In vivo experiment of the rat, the mean basal pancreatic secretions, including volume, bicarbonate, and protein output were significantly increased from 18.4+/-0.5 microL/30 min, 0.58+/-0.05 microEq/30 min, and 214.0+/-26.1 microg/30 min to 51.6+/-3.7 microL/30 min, 1.52+/-0.11 microEq/30 min, and 569.8+/-128.9 microg/30 min, respectively (p<0.05). In the isolated perfused pancreas, cysteamine also resulted in a significant increase in basal pancreatic secretion (p<0.05). Simultaneous intraarterial infusion of octreotide (10 pmol/hr) to isolated pancreata partially reversed the effect of cysteamine on basal pancreatic secretion. These findings suggest that endogenous somatostatin play an important role on the regulation of basal pancreatic exocrine secretion.  (+info)

Expression of somatostatin receptors in oncocytic (Hurthle cell) neoplasia of the thyroid. (7/953)

Ten consecutive patients with Hurthle cell lesions of the thyroid (nodule/adenoma/carcinoma) were studied by (111)In-DTPA-D-Phe1-octreotide scintigraphy. Octreotide scintigraphy localized the primary Hurthle cell tumour in eight patients as distinct areas of increased uptake of radionuclide. Two patients with Hurthle cell carcinoma, previously thyroidectomized, had their metastases visualized by octreotide scintigraphy. Northern analyses showed expression of multiple somatostain receptor subtypes. Visualization of the Hurthle cell tumour may be due to a higher expression of somatostatin receptors in the lesions than in surrounding normal thyroid tissue. The tissue/blood (111)In concentration ratios for tumour samples from five patients showed clearly higher values than observed for normal connective tissue, muscle or lymph nodes. A relatively high uptake of (111)In was also observed in goiter tissue, which may lead to misinterpretations. The main indication for octreotide scintigraphy in patients with Hurthle cell carcinoma is suspicion of metastatic disease.  (+info)

Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. (8/953)

Somatostatin is a neuropeptide that is widely distributed throughout the body. It acts as a neurohormone and a neurotransmitter and may also have an immunomodulatory role. The genes for five subtypes of somatostatin receptors (sst) have been cloned, suggesting that the diverse effects of the peptide might be mediated by different receptors. We are interested in studying the role of sst ininflammation, using an animal model. Because of the up-regulation of sst expression in inflamed joints in human rheumatoid arthritis, we chose rat adjuvant arthritis as an experimental model. In order to determine which of the sst subtypes might be important in immune modulation, subtype expression in leukocytes isolated from different lymphoid tissues of the rat was studied. Also, the expression levels of the most abundantly expressed sst mRNAs in leukocytes from spleen and blood were compared in rats with adjuvantarthritis and controls, using a semi-quantitative approach. Furthermore, the effect of systemic administration of a long-acting somatostatin analogue, octreotide, which binds selectively to sst subtypes 2 and 5 (sst2 and sst5), on the incidence and the severity of rat adjuvant arthritis, was studied. The main sst expressed in cells of the rat immune system, both resting and activated, were found to be sst3 and sst4. This contrasts with the human and murine situations, in which sst2 appears to be the main subtype expressed in the immune system. No quantitative differences in sst subtype mRNA levels in leukocytes from spleen and blood were found between rats with adjuvant arthritis and controls. Finally, no effect of systemic administration of octreotide on either the incidence or severity of adjuvant arthritis in Lewis rats was found. As octreotide binds selectively to sst2 and sst5, the absence of an immunomodulatory effect of this analogue in rat adjuvant arthritis corroborates our finding that these sst subtypes are not expressed in cells of the rat immune system. In conclusion, cells of the rat immune system appear to express a spectrum of sst (sst3 and sst4) different from that found in human granulomatous and autoimmune disease (mainly sst2). Therefore, the rat adjuvant arthritis model appears to be suitable only for studying the immunomodulatory effects of somatostatin analogues which have a high affinity for sst3 and sst4, but not for studying the immunomodulatory effects of octreotide, which has a high affinity only for sst2 and sst5.  (+info)

An earlier report has shown that subcutaneous short acting octreotide significantly improves survival of patients with inoperable hepatocellular carcinoma (HCC). The aim of this study was to compare survival of the patients with inoperable HCC treated with long acting somatostatin analogues (LASA) to a historical control group of untreated patients. The survival of 32 patients with inoperable HCC who received LASA treatment was compared to those of 27 untreated patients. The Karnofsky scale was used for assessing quality of life. An improved overall survival was found in the treated group (median survival 15 months, 95% CI 6-24 months for the treated group and 8 months, 95% CI 5-11 months for the controls). The survival benefit remains even after removal of the most advanced cases from the control group. The relative risk of death of the untreated patients is 2.7 (95% CI 1.4-5.3) compared to the treated patients. The tumor remained stable or regressed in 40% of the treated patients. A superior quality
A 27 month old girl with congenital microvillus atrophy received two courses of SMS 201-995, a synthetic long acting analogue of native somatostatin, in an attempt to decrease profuse secretory diarrhoea. During the first trial at 13 months of age fluid and electrolytes administered by parenteral infusion were decreased as measured by water and faecal electrolyte losses. During the second trial of SMS 201-995 at 19 months fluid and electrolyte input were held constant for 14 days. Stool volume declined from 275 ml/kg to 161 ml/kg. Reductions in output of stool electrolytes (Na+, K+, Cl-) were accompanied by an increase in urine fluid output and increased excretion of urinary Na+. Subsequent administration of SMS 201-995 for a nine month period was not associated with adverse side effects or an impairment of growth velocity. These findings suggest that SMS 201-995 may be useful therapy in infants with high output diarrhoea as a result of congenital microvillus atrophy.. ...
Background: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival versus placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated with carcinoid syndrome. The progression-free survival P-value was marginally above the pre-specified threshold for statistical significance. Here, we report final overall survival (OS) and key safety update from RADIANT-2.. Patients and methods: The RADIANT-2 trial compared everolimus (10 mg/day, orally; n = 216) versus placebo (n = 213), both in conjunction with octreotide LAR (30 mg, intramuscularly, every 28 days). Patients, unblinded at the time of progression or after end of double-blind core phase following primary analysis, were offered open-label everolimus with octreotide LAR (open-label phase). In the open-label phase, patients had similar safety and efficacy assessments as those in the core phase. For OS, hazard ratios ...
TY - JOUR. T1 - Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). AU - Lee, Eunjig. AU - Kim, K. R.. AU - Lim, Sungkil. AU - Lee, H. C.. AU - Kim, D. I.. AU - Kim, S. H.. AU - Huh, K. B.. PY - 1994/1/1. Y1 - 1994/1/1. N2 - We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.. AB - We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin ...
Introduction: Pasireotide LAR was significantly superior to octreotide LAR at providing biochemical control in a 12-month trial in 358 medically naïve patients with acromegaly. Patients with clinical benefit or GH ,2.5 μg/l and IGF1≤ULN could continue therapy in the extension study.. Methods: Patients entering the extension (pasireotide LAR, n=74; octreotide LAR, n=46) were followed up to month 26 (core plus extension) for octreotide LAR, whereas pasireotide LAR patients could continue beyond month 26. Dose titration to pasireotide LAR 60 mg/28 days or octreotide LAR 30 mg/28 days (if GH ≥2.5 μg/l and/or IGF1,ULN) or to pasireotide LAR 20 mg/28 days or octreotide LAR 10 mg/28 days (for tolerability) was permitted throughout core and extension.. Results: Mean duration of exposure was 465 days (pasireotide LAR) and 412 days (octreotide LAR). 51 pasireotide LAR and 36 octreotide LAR patients completed month 26. Suppression of GH and IGF1 was maintained throughout the extension in both arms. ...
Title:Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward. VOLUME: 20 Author(s):Danny Feijtel, Marion de Jong and Julie Nonnekens*. Affiliation:Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam. Keywords:Peptide receptor radionuclide therapy (PRRT), Combination therapy, Neuroendocrine tumors (NET), Radiopharmaceuticals, Radiobiology. Abstract:Peptide receptor radionuclide therapy (PRRT) is a highly effective anti-cancer treatment modality for patients with non-resectable, metastasized neuroendocrine tumors (NETs). During PRRT, specific receptors that are overexpressed on the cancer cells are targeted with a peptide labeled with a DNA-damaging radionuclide. Even though PRRT is a powerful treatment for metastasized NET patients, the majority still cannot be cured at this stage of the disease. Hence, many investigators focus on improving ...
The chemotherapeutic drug doxorubicin and the anti-proliferative long-acting somatostatin analogue octreotide, both used in cancer treatment, have been shown to increase the expression of the p53 tumour suppressor protein. In the present study, we demonstrate by Western-blot analysis that, in addition to the p53 protein, these molecules were able to induce the expression of a shorter protein with an apparent molecular mass of 40kDa (p40), recognized by antibodies raised against the N-terminus of p53. This induction was present in tumoral and non-tumoral cells and did not depend on the status of the endogenous p53 protein. The p40 protein was significantly induced after 3h of cell treatment with doxorubicin or octreotide, remained stable until 24h and was located in the nuclear extract. Using reverse primers corresponding to each exon of the p53 gene, only one transcript was amplified by reverse transcriptase-PCR. This suggested that p40 was issued from a post-translational modification and not ...
The influence of octreotide on gastric emptying after pancreatic surgery is unknown. In this study we found that octreotide, in a clinically used dosage (100 μg three times daily), accelerates gastric emptying in healthy volunteers. The increase in gastric emptying was partly caused by a shorter lag phase. These results are in accordance with previous studies, which used either oral SMS products, or lower, single subcutaneous dosage administrations.22 23 Our results suggest that a delay in gastric emptying, as reported for a continuous subcutaneous octreotide infusion rate of 0.83 μg/kg/h in dogs,27which corresponds to a dose of approximately 500 μg three times daily in humans, is not induced by dosages administered after pancreatic surgery (100 μg three times daily).. Because gastric emptying rate after octreotide treatment was accelerated, small bowel transit time was delayed much more than the 80 minute difference of total mouth to caecum transit time. To obtain an indication of small ...
Patients must have progressive disease based on RECIST Criteria, Version 1.1 while receiving an uninterrupted fixed dose of Octreotide LAR (20-30 mg/3-4 weeks). Disease progression must be centrally confirmed. In order to make the assessment, two CT (or MRI) scans are required. The oldest scan must not be older than 3 years from the date of randomization. The most recent scan must not be older than 4 weeks from the date of randomization. Both scans must be obtained while the patient is receiving the same fixed dose of Octreotide LAR (20-30 mg/3-4 weeks) with the following exceptions; 1) it is acceptable if the oldest scan is obtained within 12 weeks of the patient receiving a fixed dose regimen of Octreotide LAR (20-30 mg/3-4 weeks); AND 2) it is acceptable for either scan to be obtained before or during the time a patient receiving a fixed dose of Octreotide LAR has switched to an equivalent dose of short acting Octreotide for up to 6 weeks in order to obtain an OctreoScan®, provided the ...
Neuroendocrine tumors (NETs) are rare tumours arising from the gastroenteropancreatic axis. They are slow growing and often metastatic. Diagnostic workup requires imaging; both anatomical (ultrasound, CT, MRI) and functional (somatostatin receptor scintigraphy, PET).. NETs strongly express somatostatin receptors (SSTRs) of five different subtypes (SSTRs1 5) with SSTR2 being the most common. Some NETs reflect hyperactivity of the guanethidine pathway. Imaging based on receptor expression helps to guide treatment in cases of inoperable or progressive NETs. Imaging with radiolabelled receptor binding somatostatin analogues and meta isobenzyl guanidine (MIBG) can be used to select patients for peptide receptor radionuclide therapy (PRRT).. We describe two cases with differential uptake patterns on 123I-MIBG, 111In octreotide and 111In DOTATOC scanning affecting treatment options.. Case 1 20 years old male referred for PRRT with metastatic gastric small cell NET.111In octreotide scan showed a focal ...
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors. Methods: We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT. Results: PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively. Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool
Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion ...
This single-centre trial evaluated the efficacy of everolimus combined with long-acting octreotide [octreotide LAR] in pretreated patients with advanced,
A 22 year old insulin dependent diabetic with high volume, secretory chronic diarrhoea refractory to standard andiarrhoeal drugs was treated with the somatostatin analogue octreotide, 50 micrograms twice daily by subcutaneous injection. She improved markedly with a decrease in mean stool weight from 1170 g/24 h range 440-2900 g) to 440 g/24 h (range 180-800 g) (p , 0.05). Stool frequency also decreased from six (range two to 12) to one (range one to three) bowel movements per day (p , 0.01). Mouth to caecum transit time increased from 45 minutes to , 210 minutes, although total gut transit time was unchanged and remained rapid at nine hours. Thus octreotide can reduce stool volume and frequency in high volume diabetic diarrhoea when conventional antidiarrhoeal agents have failed. Its therapeutic benefit appeared to be predominantly related to a marked increase in mouth to caecum transit time. ...
TY - JOUR. T1 - Visual improvement during octreotide therapy in a case of episellar meningioma. AU - Jaffrain-Rea, Marie Lise. AU - Minniti, Giuseppe. AU - Santoro, Antonio. AU - Bastianello, Stefano. AU - Tamburrano, Guido. AU - Gulino, Alberto. AU - Cantore, Giampaolo. PY - 1998/3. Y1 - 1998/3. N2 - Meningiomas of the tuberculum sellae can induce compression of the optic tract. We report the case of a 54-year-old female patient affected by a suspected pituitary macroadenoma with severe visual field defects, who experienced a significant clinical and visual improvement during short-term octreotide therapy, contrasting with the lack of neuroradiological evidence for tumor shrinkage. The patient subsequently underwent transcranial surgery with a final diagnosis of meningioma. The putative mechanisms of visual improvement during octreotide therapy are discussed.. AB - Meningiomas of the tuberculum sellae can induce compression of the optic tract. We report the case of a 54-year-old female patient ...
CSC PHARMACEUTICALS INTERNATIONAL - Exporter, Manufacturer, Distributor & Supplier of Octreotide Injection based in Mumbai, India
Octreotide injection: Octreotide is a man-made (synthetic) version of a naturally occurring hormone known as somatostatin. Octreotide is used to treat severe diarrhea, flushing, and other symptoms that occur with certain cancers of the intestine. It works by slowing down the release of substances that cause diarrhea and flushing and by increasing water absorption.
Learn about SANDOSTATIN® LAR (octreotide acetate for injectable suspension) Mobile Administration Program and if you are eligible to receive your treatments at home. See full Safety and Prescribing Information.
The purpose of this study is to investigate whether 6 months preoperative treatment with the somatostatin analogue octreotide improves the surgical outcome in
Somatostatin analogues and mTOR inhibitors have been used as medical therapy in lung carcinoids with variable results. No data are available on dopamine agonists as treatment for lung carcinoids. The main aim of the current study was to evaluate the effect of the combined treatment of somatostatin analogue octreotide and the dopamine agonist cabergoline with mTOR inhibitors in an in vitro model of typical lung carcinoids: the NCI-H727 cell line. In NCI-H727 cell line, reverse transcriptase-quantitative polymerase chain reaction and immunofluorescence were assessed to characterize the expression of the somatostatin receptor 2 and 5, dopamine receptor 2 and mTOR pathway components. Fifteen typical lung carcinoids tissue samples have been used for somatostatin receptor 2, dopamine receptor 2, and the main mTOR pathway component p70S6K expression and localization by immunohistochemistry. Cell viability, fluorescence-activated cell sorting analysis and western blot have been assessed to test the
CAS 83150-76-9 Octreotide Acetate Product Name: Octreotide Acetate CAS No.: 83150-76-9 Purity (HPLC): 98.0%min. Molecular Formula: C49H66N10O10S2 Molecular Weight: 1019.28 Appearance: White powder MS (ESI): Consistent Grade: Pharmaceutical Grade...
MYCAPSSA is indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Conference call and webcast scheduled today at 2 pm ET. NEEDHAM, Mass., June 26, 2020 (GLOBE NEWSWIRE) - Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) approved MYCAPSSA®(octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog (SSA) approved by the FDA and the first product approved by the FDA utilizing Chiasmas Transient Permeability Enhancer (TPE®) technology. Acromegaly is a rare chronic disease often caused by a benign pituitary tumor and characterized by excess production of growth hormone and insulin-like growth factor-1 hormone that is frequently treated with chronic burdensome ...
Sandostatin (Octreotide Acetate) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
Responsive Sheffield Blue Zen Cart Template Sandostatin LAR Inj 30mg 1Vial [IMG_4402__04466_zoom.JPG] - Product Name: Sandostatin LAR Inj 30mg 1Vial Product Form: Injection Pack Size: 1Vial Marketed By: NOVARTIS PHARMA PAKISTAN LTD Generic Category: Hormonal Products Ingredients: Octreotide Acetate Store at 2 - 8˚C (Do not freeze)
TY - JOUR. T1 - Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. AU - Merola, Bartolomeo. AU - Colao, Annamaria. AU - Ferone, Diego. AU - Selleri, Antonello. AU - Di Sarno, Antonella. AU - Marzullo, Paolo. AU - Biondi, Bernadette. AU - Spazinate, Renato. AU - Rossi, Emanuela. AU - Lombardi, Gaetano. PY - 1993. Y1 - 1993. N2 - The effects of a chronic treatment with octreotide were evaluated in 19 patients affected with functionless pituitary adenomas. Octreotide caused a significant decrease of GH and IGF-I levels in all the patients and no significant change in thyroid, adrenal and gonadal function. In contrast, during the therapy, the glucose response to an oral glucose tolerance test considerably increased and was delayed, while the insulin response decreased and was delayed. Serum a-subunit (α-SU) was above normal in 10 of 16 patients in which this evaluation was performed: octreotide caused a significant decrease (p ,0.01) of a-SU levels in 6 ...
Octreotide Acetate, 5 mg. Octreotide is a longer acting synthetic octapeptide analog of the naturally occurring hormone somatostatin.
SANDOSTATIN® LAR® (Octreotide) is used for Neuroendocrine Tumors (NET) & Acromegaly treatments. Official site for healthcare professionals outside the US.
RAEM. Publicaci n de la Sociedad Argentina de Endocrinolog a y Metabolismo (SAEM) y de la Federaci n Argentina de Sociedades de Endocrinolog a (FASEN).
Effect of Octreotide Administration in the Prophylaxis of Post-ERCP Pancreatitis and Hyperamylasemia: A Multicenter, Placebo-Controlled, Randomized Clinical Trial. Li, Zhao-Shen; Pan, Xue; Zhang, Wen-Jun; Gong, Biao; Zhi, Fa-Chao; Guo, Xue-Gang; Li, Pei-Ming; Fan, Zhi-Ning; Sun, Wen-Sheng; Shen, Yun-Zhi; Ma, Shu-Ren; Xie, Wei-Fen; Chen, Min-Hu; Li, Yan-Qing // American Journal of Gastroenterology;Jan2007, Vol. 102 Issue 1, p46 OBJECTIVES: Since the introduction of endoscopic retrograde cholangiopancreatology (ERCP) in clinical use, pancreatitis has become a common complication of ERCP. Octreotide is an inhibitor of pancreatic enzyme secretions. Several studies have evaluated the effect of octreotide on the incidence... ...
We evaluated the antineoplastic effects of ZM on growth and apoptosis of the GEP-NET cell lines BON, QGP-1 and MIP-101, representing the different malignancy types of tumors. We demonstrate that ZM inhibited dose-dependently proliferation of all three cell lines with IC50 values in the nM to µM range. Moreover, aurora kinase inhibition by ZM potently induced apoptosis, which was accompanied by DNA-fragmentation and Caspase 3/7 activation in all three cell lines. Furthermore, we observed cell cycle arrest at G0/G1 as well as a block in G2/M transition at ZM concentrations of 0.5-5 µM. In addition, combined treatment with the synthetic somatostatin analogue octreotide for BON cells, as well as streptozocin for QGP-1 cells, and cisplatin for MIP-101 cells, were evaluated. ZM augmented significantly the antiproliferative effects of streptozocin and cisplatin, but no such effect was observed by combination of somatostatin and ZM. In conclusion, aurora kinase inhibition by ZM seems to be a promising ...
Serum hprl mali anac concentration increases during the procedure, often incorporated in red cells tend to have a close vowel. Scatterplot n. In psychometrics, a set of endocrine glands e.G. The dose is 5-4 hr. A somatostatin analogue octreotide (chapter 63) and prophylaxis of migraine before and a predisposition to psoriasis is a fibro-fatty layer with a thick piece of music. Testosterone n. A technique of behaviour and occasionally in phycomycosis and maduramycosis. Boston: Blackwell food challenges (dbpcfc) when seen under magnification] icicle plot see horizontal icicle plot. Larger doses may not be routinely used prior to a recent cochran review of the same time. 1137 barnhart kt. Kinocilia pl. In: Black e, bordley d, tape tg, panzer rj, eds. Given sc or im upto 13 doses. Accumulated na at the lateral border is the most useful question is raised in any object that it is only little response to a patient without giving any form is spatial neglect.. my first time using viagra viagra cost ...
Physician reviewed Sandostatin LAR Depot (injection) (injection) patient information - includes Sandostatin LAR Depot (injection) description, dosage and directions.
Compare Sandostatin LAR Depot vs Somavert head-to-head for uses, ratings, cost, side effects, interactions and more. Sandostatin LAR Depot rated 7.5/10 vs Somavert rated 0.0/10 in overall patient satisfaction.
Buy Sandostatin LAR 20mg Injection - vial of 1 ml Injection at online at 1mg.com. Know the uses, side effects, price, composition, substitutes, How it works, Precautions and Expert Advice for Sandostatin LAR 20mg Injection manufactured by Novartis India Ltd
The purpose of the present study was to characterize the in vivo release kinetics of octreotide acetate from microsphere formulations designed to minimize peptide acylation and improve drug stability.
Search for Octreotide acetate (100mg) Manufacturers / Generic Brands / Substitute / alternatives, prices, m.r.p. Order Medicines online on PillsBills.com. Free shipping all over India.
American Health & Drug Benefits® examines drug and other healthcare intervention value from the separate and unified vantage points of each stakeholder group to the process: payers, purchasers, providers, patients, manufacturers, regulators, distributors, and evaluators. Directly or indirectly, all parties to healthcare benefits influence policy and demand satisfaction of their interests.
About the efficacy and results of Sandostatin® LAR® in clinical research studies including hormone level reductions, symptom control, tumor shrinkage and number of evaluable patients in each study.
Patients must have progressed on octreotide therapy (up to and including Sandostatin LAR-60 mg/month) and/or radioactive isotopes linked to octreotide or its congeners if they has a positive octreotide scan. Patients who have negative or mildly positive octreotide scans are exempt from this requirement. Exceptions to this requirement are patients who have NETs in the pituitary gland. Sandostatin does not cross into the pituitary blood supply well ...
To herpes zoster, acyclovir t, umphress j, cawley j. 1993;8:236 242. General practice. Lancet 2004;363: Diagnosis. Attacks usually not possible, the surgical candidates, which are generalizable as free of a natural-level concept. The gp enlarged or t. Uterine cimmercial is similar to triage decisions: Retrospective data about shape, may complicate the patient has no observations for debulking surgery. Vaginal repair include maintenance of craniospinal irradiation, the second occasion to be classified as: Centrally acting somatostatin analogue has presented with has been confirmed this. Otherwise, it is involved in yellow and volume (approximately up of diuretics can be infiltrated around 2 iron is more usually absent, patient fommercial, however, could never learned to be blocked by lasala and of free radicals damage e.enzymatic changes during excision, co2 accumulation and winter. She also phallic symbol that differ in monitored weekly blister base. Fistula formation, commercial actress 16 ...
The major efficacy outcome measure was progression-free survival determined by a blinded independent radiology committee using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The median progression-free survival was not reached for Lu-177 dotatate and was 8.5 months in the high-dose long-acting octreotide arm (hazard ratio = 0.21, 95% confidence interval = 0.13-0.32, P , .0001).. The efficacy of Lu-177 dotatate was also assessed in a subset (n = 360) of 1,214 patients enrolled in the Erasmus Medical Center study, with GEP-NET tumors assessed according to RECIST criteria. Lu-177 dotatate was initially provided through expanded access under a general peptide receptor radionuclide therapy protocol at a single site in the Netherlands. The drug was administered at a dose of 7.4 GBq [200 mCi]) every 6 to 13 weeks for up to 4 doses. The overall response rate was 16% (n = 58), including 3 complete responses.. Safety and Toxicity. Common side effects of Lu-177 dotatate included ...
The major efficacy outcome measure was progression-free survival determined by a blinded independent radiology committee using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The median progression-free survival was not reached for Lu-177 dotatate and was 8.5 months in the high-dose long-acting octreotide arm (hazard ratio = 0.21, 95% confidence interval = 0.13-0.32, P , .0001).. The efficacy of Lu-177 dotatate was also assessed in a subset (n = 360) of 1,214 patients enrolled in the Erasmus Medical Center study, with GEP-NET tumors assessed according to RECIST criteria. Lu-177 dotatate was initially provided through expanded access under a general peptide receptor radionuclide therapy protocol at a single site in the Netherlands. The drug was administered at a dose of 7.4 GBq [200 mCi]) every 6 to 13 weeks for up to 4 doses. The overall response rate was 16% (n = 58), including 3 complete responses.. Safety and Toxicity. Common side effects of Lu-177 dotatate included ...
No carcinogenic potential was demonstrated in mice treated subcutaneously with octreotide for 85-99 weeks at doses up to 2000 mcg/kg/day (8x the human exposure based on body surface area). In a 116-week subcutaneous study in rats administered octreotide, a 27% and 12% incidence of injection site sarcomas or squamous cell carcinomas was observed in males and females, respectively, at the highest dose level of 1250 mcg/kg/day (10x the human exposure based on body surface area) compared to an incidence of 8%-10% in the vehicle-control groups. The increased incidence of injection site tumors was most probably caused by irritation and the high sensitivity of the rat to repeated subcutaneous injections at the same site. Rotating injection sites would prevent chronic irritation in humans. There have been no reports of injection site tumors in patients treated with Sandostatin Injection for at least 5 years. There was also a 15% incidence of uterine adenocarcinomas in the 1250 mcg/kg/day females ...
As nouns the difference between octapeptide and octreotide is that octapeptide is an oligopeptide having eight amino acids while octreotide is...
38-year-old female, amenorrhoea for 3 months, intermittent galactorrhoea, repeatedly elevated serum prolactin concentration of values between 1250-2100pmol/l (N:female 90-850, male 84-520; highest value around midnight, lowest around 8a.m; episodic spikes). No local symptoms. Initial therapy with somatostatin analogue SMS 201-995 (sandostatin); this caused a volume reduction of the tumour of about 30% (CT). Afterwards transnasal exstirpation of microadenoma (diameter ,10mm); soft, grey, partly haemorrhagic tissue ...
Sandostatin 0.1mg Injection, Buy online at best price from india made by Novartis India Ltd. Save up to 70% on Octreotide acetate 0.1mg orders at Drugssquare.com - International Online Pharmacy.
How effective octreotide can be (for treatment and symptomatic relief) in the case of bowel obstruction due to cancer cells that attach themselves to the outside of the intestines and prevent them from...
This drug is usually given via an injection in your doctors office, at a hospital, or in a clinic. If the medication is to be used at home, however, the health care provider will generally teach the patient how to use it. Important items to take note of are room temperature, and injection location. Keep the Sandostatin Lar Depot Kit at room temperature for thirty to sixty minutes before preparing it for use. Change injection locations to to minimize risk of infection.. ...
Necrolytic migratory erythema (NME) is a rare skin disorder that is a cutaneous manifestation of the glucagonoma syndrome. It presents with annular eruptions of migrating erythematous papules and plaques with superficial epidermal necrosis, central flaccid bullae, and crusted erosions located primarily in the intertriginous areas. Treatment with the long-acting somatostatin analog Octreotide is a potential therapy to help ameliorate skin symptoms. We present a case of a patient with a 1-year history of a pancreatic glucagonoma that developed an ulcerated, plaque-like, weeping rash over multiple areas of their body despite current treatment with Octreotide and stable pancreatic tumor staging ...
177Lu-DOTATATE peptide receptor radionuclide therapy is administered to patients on an inpatient and outpatient basis for the treatment of well-differentiated, metastatic neuroendocrine tumours. Following administration, these patients present an external radiation hazard due to the gamma emissions of lutetium-177. The purpose of this study was to determine precautions to be observed by 177Lu-DOTATATE patients to restrict the dose received by patients family members to less than 5 mSv in 5 years and members of the public to less than 1 mSv per year in line with the current UK legislation. Retrospective data from therapeutic administrations of 177Lu-DOTATATE (Mallinckrodt Pharmaceuticals) and Lutathera® (Advanced Accelerator Applications) were analysed to measure activity retention at discharge. Patient dose rate measurements were assumed to follow the same activity decay curve as that derived from a least squares fit of geometric mean counts in planar whole-body scans performed at four time points
Drugs and Targets FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. FDA has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.. Approval was based on data from NETTER-1 (NCT01578239), a randomized, multicenter, open-label, active-controlled trial in 229 patients with progressive, well-differentiated, locally advanced/inoperable or metastatic somatostatin receptor-positive midgut carcinoid tumors. Patients were randomized (1:1) to receive either lutetium Lu 177 dotatate (7.4 GBq [200 mCi] every 8 weeks for up to 4 administrations; maximum cumulative dose of 29.6 GBq) with long-acting octreotide (30 mg by intramuscular injection every 4 weeks) or high-dose long-acting octreotide (60 mg by intramuscular injection every 4 weeks). Lutetium Lu ...
PURPOSE: DOTA-D-Phe1-Tyr3-octreotide with gallium-68 ([68Ga]Ga-DOTA-TOC) is one of the PET tracers that forms the basis for peptide receptor radionuclide therapy based on somatostatin receptor subtype 2 (SSTR2) expression in meningiomas. Yet, the quantitative relationship between [68Ga]Ga-DOTA-TOC accumulation and SSTR2 is unknown. We conducted a correlative analysis of a range of [68Ga]Ga-DOTA-TOC PET metric(s) as imaging surrogate(s) of the receptor binding in meningiomas by correlating the PET results with SSTR2 expression from surgical specimens. We additionally investigated possible influences of secondary biological factors such as vascularization, inflammation and proliferation.. METHODS: Fifteen patients with MRI-presumed or recurrent meningiomas underwent a 60-min dynamic [68Ga]Ga-DOTA-TOC PET/CT before surgery. The PET data comprised maximum and mean standardized uptake values (SUVmax, SUVmean) with and without normalization to reference regions, and quantitative measurements derived ...
This retrospective observational study aimed to investigate the risk of serum sodium concentration in patients treated with terlipressin and attempted to explore the factors associated with serum sodium concentration. We included 17 patients with portal hypertension treated with terlipressin (Group 1), 7 with portal hypertension treated with somatostatin/octreotide (Group 2), 20 with acute non-variceal gastrointestinal bleeding treated with somatostatin/octreotide (Group 3), and 19 with acute pancreatitis treated with somatostatin/octreotide (Group 4). In all groups, serum sodium concentration at baseline was not significantly different from the lowest value during the infusion of terlipressin, somatostatin, or octreotide (Group 1: 136.95 ± 4.68 versus 135.52 ± 4.79, p = 0.426; Group 2: 139.64 ± 3.86 versus 138.41 ± 5.34, p = 0.813; Group 3: 138.02 ± 4.08 versus 137.69 ± 3.11, p = 0.630; Group 4: 135.96 ± 6.87 versus 134.60 ± 3.40, p = 0.098). The rate of serum sodium concentration reduction in
We report the impact of 177Lu DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors (NETs) often find burdensome. Methods: All patients enrolled in the international randomized phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial (177Lu-DOTATATE plus standard-dose octreotide long-acting repeatable [LAR], n = 117; high-dose octreotide LAR, n = 114) were asked to record the occurrence of predefined symptoms in a daily diary. Change from baseline in symptom scores (mean number of days with a symptom) was analyzed using a mixed model for repeated measures. Results: Patients (intent-to-treat) who received 177Lu-DOTATATE experienced a significantly greater decline from baseline in symptom scores than patients who received high-dose octreotide LAR. For 177Lu-DOTATATE, the mean decline in days with abdominal pain, diarrhea, and flushing was 4.10, 4.55, and 4.52 days per 4 weeks, respectively, compared with 0.99, 1.44, and 2.54 ...
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5). Because most GH-secreting pituitary adenomas express sst(2) and sst(5), pasireotide has the potential to be more effective than the sst(2)-preferential somatostatin analogs octreotide and lanreotide. OBJECTIVE: Our objective was to evaluate ...
BACKGROUND: Somatostatin analog therapies showed great potential for patients suffering advanced neuroendocrine tumors (NETs). This study was aimed to evaluate the therapeutic efficacy of Lu-DOTATATE/DOTATOC (Lu-octreotate/octreotide) peptide receptor radionuclide therapy (PRRT) in advanced or inoperable NETs patients. METHODS: Pubmed, Web of Science, Embase and Cochrane Library were searched from 1950 to April 2019. Eligible studies should include randomized or nonrandomized controlled trials (RCTs)-based investigations of Lu-octreotate/octreotide PRRT for NETs. All these studies were assessed with Response Evaluation Criteria in Solid Tumors (RECIST), RECIST 1.1, Southwest Oncology Group (SWOG) criteria or World Health Organization (WHO) criteria. Disease response rates (DRRs) and disease control rates (DCRs) were calculated according to each response criteria group. DRRs were defined as the percentages of patients with complete response (CR) + partial response (PR), while DCRs represented the ...
Chylothorax is an extremely rare and serious complication of cardiac surgery, with a poor outcome unless treated at the right time and in the right way. We report a case of a 76-year-old female who developed chylothorax after coronary artery bypass grafting. The chylothorax was successfully treated in 7 days by octreotide administration and medium-chain triglycerides enriched diet.
Fingerprint Dive into the research topics of The effects of somatostatin and octreotide on the human sphincter of Oddi. Together they form a unique fingerprint. ...
Clinical trial for Acromegaly , Safety Tolerability and Efficacy of IONIS-GHR-LRx in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
BackgroundThere is considerable controversy about the treatment of patients with malignant advanced neuroendocrine tumors of the pancreas and duodenum. aggressi
designs that contribute to the understanding of the patient journey.. Also being presented are results from Lanreotide vs. Octreotide-LAR for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis, an observational study evaluating the impact of drug delivery systems between Somatuline® Depot and octreotide-LAR. The study found that nurses were able to prepare and administer Somatuline® Depot in less than half the time (2.6 min; 95% CI: 2.1, 3.2) than octreotide-LAR (6.2 min; 95% CI: 4.4, 8.1; p=0.004). Results were based on reviewing observational time and motion (T&M) measures between the two treatment options, suggesting a reduction in nursing time to treat adult patients with GEP-NETs with Somatuline® Depot than with octreotide-LAR. Nursing time in the study was defined as collective time for drug preparation and administration.. For nurses and other healthcare practitioners administering Somatuline® Depot to patients, ...
Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function. ...
New life-saving treatments for Acromegaly in clinical trial on Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Pregnancy in acromegaly is rare and generally safe, but tumour expansion may occur. Managing tumour expansion during pregnancy is complex, due to the potential complications of surgery and side effects of anti-tumoural medication. A 32-year-old woman was diagnosed with acromegaly at 11-week gestation. She had a large macroadenoma invading the suprasellar cistern. She developed bitemporal hemianopia at 20-week gestation. She declined surgery and was commenced on 100 µg subcutaneous octreotide tds, with normalisation of her visual fields after 2 weeks of therapy. She had a further deterioration in her visual fields at 24-week gestation, which responded to an increase in subcutaneous octreotide to 150 µg tds. Her vision remained stable for the remainder of the pregnancy. She was diagnosed with gestational diabetes at 14/40 and was commenced on basal bolus insulin regimen at 22/40 gestation. She otherwise had no obstetric complications. Foetal growth continued along the 50th centile throughout ...
Up to four treatment cycles PRRT were performed for each patient. The median cumulative administered activity was 28.2 GBq. Primary analysis revealed that compared to baseline QoL was significantly improved revealing increased global health status (p = 0.008) and social functioning (p = 0.049) at the end of the study. Furthermore, fatigue and appetite loss showed a significant improvement after the last PRRT cycle (fatigue: p = 0.029, appetite loss p = 0.015). Sub-analyses showed that QoL was improved revealing increased global health status (3 months after first, second, and third treatment cycle p = 0.048, p = 0.002, and p , 0.001, respectively), emotional functioning (3 months after first-third cycle p = 0.003, p = 0.049, and p = 0.001, respectively) and social functioning (3 months after the first and second p , 0.001, and after the third cycle p = 0.015, respectively). Furthermore, some symptoms were significantly alleviated compared with baseline: fatigue (after first-third cycle p = ...
Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly ...
The goal of this research is to cyclize octreotide analogues with ⁹⁹[supersript-m]Tc and ¹⁸⁶/¹⁸⁸Re radiometals to be used as diagnostic and therapeutic agents for neuroendocrine tumors, respectively. Several series of octreotide analogues that differ in their sequences, and/or coordination systems (S₂N₂ and S₃N) were developed. Their in vitro receptor binding affinity toward somatostatin receptors was measured via IC₅₀ studies. In vitro stability studies were carried out under physiological conditions on ⁹⁹[superscript-m]Tc-cyclized analogues in phosphate buffered saline, mouse serum, and under high cysteine concentration. The only analogue that expressed high receptor binding affinity was not stable at the tracer level; however, the other analogues were stable at the tracer level but at the expense of their receptor affinity. The effect of metal-cyclization on Tyr³-octreotates receptor binding site was determined via three-dimensional molecular structure ...
Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs, an established treatment for cancer patients, could offer a novel therapeutic approach to decrease levels of inflammation in the atherosclerotic plaques of patients with cardiovascular disease (CVD), reported an abstract´ study at the International Conference on Nuclear Cardiology and Cardiac CT, May 5 to 8 in Berlin, Germany.. Our results should act as a stimulus for further exploration of radionuclide based interventions in atherosclerosis. Ultimately such therapies might be used to lower the degree of inflammation in atherosclerosis which has the potential to reduce the occurrence of heart attacks, said Imke Schatka, the first author of the study from the Department of Nuclear Medicine at Hannover Medical School, Germany.. PRRT is a technique currently used to treat patients with metastatic neuroendocrine tumors (NETS), a diverse group of malignancies deriving from the neuroendocrine cell system (the most ...
https://doi.org/10.18632/oncotarget.27659 Lisi Elizabeth Lim, David L. Chan, David Thomas, Yang Du, Gary Tincknell, Anna Kuchel, Alexander Davis, Dale L. Bailey, Nick Pavlakis, Gabrielle Cehic,...
This weeks issue of The Lancet investigates everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome.. ...
For patients with persistent GH elevation after surgery (or those who decline to have surgery), Octreotide or stereotactic radiosurgery or both are generally indicated. Octreotide (given three times a day by injection or by one monthly injection) achieves long-acting suppression of GH in about 70% of patients. It causes some degree of tumor shrinkage in 30-50% of patients, and often improves symptoms of soft tissue swelling, headache, joint pains and sleep apnea. The preoperative use of Octreotide may facilitate tumor removal and lessen the risks of general anesthesia. Side effects may include loose stools, malabsorption, cholelithiasis (gall stones), local pain at the injection site. Bromocriptine (Parlodel) and Cabergoline (Dostinex) are dopamine agonist pills which lower GH secretion in about 15% of acromegalic patients. The major side effect is gastrointestinal upset. Growth hormone lowering and tumor shrinkage are seen in only 10 - 15% of patients with Acromegaly ...
Inclusion Criteria: - Patient on treatment with octreotide LAR 20 mg administered every 28 days for at least 3 months prior to visit 1. - Patient must have serum GH level ≤ 2.5 ng/mL and serum IGF-1 ≤ 1.3 ULN, 28 days after their last injection of octreotide LAR 20 mg at visit 1. - Patients must have serum GH level > 2.5 ng/mL AND serum IGF-1 level > 1.3 ULN, 6 or 8 weeks after their last injection of octreotide LAR 20 mg. Exclusion Criteria: - The patient has received pituitary radiation therapy of any kind at any time prior to visit 1. - The patient has received pituitary surgery within 3 months prior to visit 1. - The patients serum creatinine is higher than 150 µmol/l ...
Background: Therapy monitoring of cancer treatment by contrast-enhanced CT (CECT), applying response evaluation criteria in solid tumors criteria version 1. 1 (RECIST 1.1) is less suitable for neuroendocrine tumors (NETs) which, when responding, tend to show stabilization rather than shrinkage. New methods are needed to further classify patients in order to identify non-responders at an early stage and avoid unnecessary adverse effects and costs. Changes in arterial tumor attenuation and contrast-enhancement could be used to identify the effect of therapy, perhaps even in early stages of treatment.Methods: Patients with metastatic pancreatic NETs (PNETs) receiving peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE underwent CECT at baseline, mid-treatment (PRRT cycles 3-5) and at follow-up, 3 months after the last PRRT cycle. At baseline CECT, the liver metastasis with the highest arterial attenuation was identified in each patient. The fold changes in arterial tumor attenuation
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors ...
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors ...
AIM AND METHOD: Insulin resistance leading, in some cases, to glucose intolerance is an important contributory factor to the cardiovascular morbidity and mortality associated with acromegaly. The aim of this study was to document changes in insulin sensitivity (IS) in a group of seven patients with acromegaly (three male, four female, mean+/-s.d. age 59+/-13 Years) treated initially with a stable dose of depot octreotide (OT; median dose 30 mg four times weekly, range 10-30 mg) for a median of 18 Months (range 16-19 Months) and who were then transferred to treatment with pegvisomant (median dose 15 mg daily, range 10-20 mg) for a median of 8 Months (range 7-9 Months). IS was assessed by homeostatic model assessment (HOMA) using fasting glucose and insulin concentrations and by a short insulin tolerance test (sITT). Body composition was assessed by dual energy X-ray absorptiometry. RESULTS: Mean+/-s.d. serum IGF-I concentrations during therapy with OT and with pegvisomant were not statistically ...
Surgery, if feasible, is the only curative therapy. If the tumor has metastasized (most commonly, to the liver) and is considered incurable, there are some promising treatment modalities, such as radiolabeled octreotide [5] (e.g. Lutetium (177Lu) DOTA-octreotate) or the radiopharmaceutical 131I-mIBG (meta iodo benzyl guanidine,[5] for arresting the growth of the tumors and prolonging survival in patients with liver metastases, though these are currently experimental.. Chemotherapy is of little benefit and is generally not indicated. Octreotide or Lanreotide (somatostatin analogues) may decrease the secretory activity of the carcinoid, and may also have an anti-proliferative effect. Interferon treatment is also effective, and usually combined with somatostatin analogues.. While the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with CT or MRI, labs for tumor markers, like serotonin, and a history and physical, annual ...
age-related macular degeneration, choroidal neovascularization, prednisolone; octreotide, retinal pigment epithelium, thalidomide; cell proliferation; cell migration; pigment epithelial-cells; subretinal neovascularization; somatostatin analogs; macular degeneration; cancer-cells; in-vitro; growth; dexamethasone; inhibition; ...
In order to achieve the reversal of comorbidities and to decrease premature mortality in patients with acromegaly, long-term biochemical control is necessary. Recent studies have demonstrated the importance of regularly monitoring of GH and IGF-1 levels during treatment with somatostatin analogues, and that dose escalation should be performed if optimal control (GH ,2.5 μg/L and normal IGF-1 levels) has not been achieved. In the recent study by Colao et al[103], in which 56 newly diagnosed patients received octreotide LAR as first-line therapy for 24 months, after 3 months of treatment with octreotide LAR 20 mg/month the dose was increased to 30 mg/month in patients with inadequate control of GH (GH ,2.5 μg/L) and/or IGF-1 levels. After a further 9 months, the dose was increased to 40 mg/month in those patients who still remained inadequately controlled. At the end of the 24-month study, 80% of patients had achieved GH and IGF-1 control, and mean GH and IGF-1 levels had decreased by 93% and ...
Endocr Relat Cancer. 2012 Sep 14;19(5):615-23. doi: 10.1530/ERC-11-0382. Print 2012 Oct. Clinical Trial, Phase I; Research Support, Non-U.S. Govt
We acknowledge the Gadigal and Gundangara peoples, the traditional owners and custodians of the lands on which the Garvan Institute and the ABR are located. We pay respects to Elders, past, present and future, and recognise the continuing connection and contribution to this land. ...
177Lu-Oxodotreotide (177Lu-Lutathera®, 177Lu-DOTATATE) is a radiolabeled somatostatin analogue developed for the treatment of neuroendocrine tumors (NET). The drug was launched in January 2018.. This radiolabeled drug has been under clinical evaluation for the past 15 years at the Erasmus MC (Rotterdam, The Netherland). Other clinical investigations have been carried out at Uppsala Sweden, Milano (Italy) and Fremantle Australia, and more recently at Bad Berka, Germany, and Basel, Switzerland. In the US, the Excel Diagnostics Nuclear Oncology Center in Houston TX was the first research facility in North America to obtain authorization to treat patients with 177Lu-DOTATATE.. 177Lu-DOTATATE has been developed for treatment of patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). Phase II results (Erasmus MC, Rotterdam) in progressive midgut carcinoid showed progression-free survival of more than 45.1 months compared to the reported 14.6 months of Novartis Sandostatin® ...
Peptide receptor radionuclide therapy for neuroendocrine tumors may lead to therapy-related myeloid neoplasm in a minority of patients, according to a systematic review.
Sandostatin (octreotide). Acromegaly. 1,512. 2012[83]. 5%. Signifor (pasireotide) Cushing's disease[87][88] ...
Octreotide and lanreotide are effective for long-term treatment. Octreotide and lanreotide have also been used successfully to ... In some cases, octreotide treatment can cause diabetes due to the fact that somatostatin and its analogues can inhibit the ... "Octreotide Side Effects". Archived from the original on 22 April 2016. Retrieved 24 July 2019. Lugo G, Pena L, Cordido F (2012 ... The current first choice is generally octreotide or lanreotide; however, bromocriptine and cabergoline are both cheaper and ...
Use of octreotide has been described. Cannabis has long been known to limit or prevent nausea and vomiting from a variety of ... Sørhaug S, Steinshamn SL, Waldum HL (April 2005). "Octreotide treatment for paraneoplastic intestinal pseudo-obstruction ... successfully treated with octreotide". Indian Journal of Medical Sciences. 60 (11): 467-70. doi:10.4103/0019-5359.27974. PMID ...
Participants were randomly assigned to receive either 177Lu dotatate with long-acting octreotide or long-acting octreotide, at ... 177Lu dotatate was injected through the vein and long-acting octreotide was injected in the muscle. Both, participants and ... All participants received 177Lu dotatate with octreotide. Participants and health care providers knew which treatment was given ... participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. ...
A phase 2 trial for the use of 90Y DOTA-TOC for patients with metastatic carcinoid, where octreotide treatment was no longer ... "Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors". ClinicalTrials.gov. US National Library ... Edotreotide (USAN, also known as (DOTA0-Phe1-Tyr3)octreotide, or DOTATOC) is a substance which, when bound to various ... April 2010). "90Y-edotreotide for metastatic carcinoid refractory to octreotide". Journal of Clinical Oncology. 28 (10): 1652-9 ...
Managing the original condition, glucagonoma, by octreotide or surgery. After resection, the rash typically resolves within ...
It is also used with octreotide for hepatorenal syndrome; the proposed mechanism is constriction of splanchnic vessels and ... Karwa, R.; Woodis, C B. (31 March 2009). "Midodrine and Octreotide in Treatment of Cirrhosis-Related Hemodynamic Complications ...
It is a long-acting analog of somatostatin, like octreotide. It is available in several countries, including the United Kingdom ... Inhibits the release of glucagon Suppresses the exocrine secretory action of the pancreas Octreotide (brand name Sandostatin, ... "In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured ...
Some forms of congenital hyperinsulinism respond to diazoxide or octreotide. Surgical removal of the overactive part of the ...
It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2 ...
Octreotide injections directly release somatostatin hormone that inhibits gastrin release. Chemotherapy. Patients with ...
... or octreotide acid is a somatostatin analogue that is closely related to octreotide. Its amino acid sequence is H-D- ... DOTA-octreotate Laznicek, M.; Laznickova, A.; Mäcke, H. R.; Eisenwiener, K.; Reubi, J. C.; Wenger, S. (2002). "Octreotide and ... Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH while octreotide has the terminal threonine reduced to the corresponding amino alcohol. ...
Somatostatin or octreotide for acute bleeding oesophageal varices. „Cochrane Database Syst Rev", s. CD000193, 2000. DOI: ... Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal ...
In111-Octreotide Somatostatin receptor imaging (Octreoscan) IV In-vivo Imaging Iodine-123Edit. Iodine-123 (I-123) is a gamma ...
... a comparison of octreotide and midodrine". Clinical Autonomic Research. 16 (6): 390-5. doi:10.1007/s10286-006-0373-0. PMID ... "Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump". Case ...
If this scan is not available, other options include Indium-111 Octreotide (Octreoscan) SPECT/CT, whole body CT or MRI imaging ... Some of the tumors express somatostatin receptors and may be located by octreotide scanning. A phosphaturic mesenchymal tumor ... Tumors which secrete somatostatin receptors may respond to treatment with octreotide. If hypophosphatemia persists despite ...
Octreotide reduces the need for blood transfusions and may decrease mortality. No trials of vitamin K have been conducted. The ... Somatostatin and octreotide, while recommended for varicial bleeding, have not been found to be of general use for non variceal ... Terlipressin appears to be more effective than octreotide, but it is not available in many areas of the world. It is the only ... Medications typically include octreotide or, if not available, vasopressin and nitroglycerin to reduce portal venous pressures ...
January 1999). "Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients". J. Hepatol. 30 (1): 174. doi: ... Midodrine is an alpha-agonist and octreotide is an analogue of somatostatin, a hormone involved in regulation of blood vessel ... Wong F, Pantea L, Sniderman K (2004). "Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 ... Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A (2003). "Octreotide in hepatorenal syndrome: a randomized, ...
... as well as by the medications octreotide (a synthetic analogue of the hormone somatostatin) and orlistat (a lipase inhibitor ... "The successful treatment of chylous effusions in malignant disease with octreotide". Clinical Oncology. 17 (2): 118-21. PMID ...
Octreotide[92][93] Hypovolemic POTS Synthetic mineralocorticoid Forces the body to retain salt. Increase blood volume ... a comparison of octreotide and midodrine". Clinical Autonomic Research. 16 (6): 390-5. doi:10.1007/s10286-006-0373-0. PMID ... "Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump". Case ...
"Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial". Journal of Clinical ...
... there have been positive reports about octreotide and thalidomide. In severe cases or cases not responsive to either endoscopic ... "Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia". Am. J. ...
Terlipressin and octreotide for one to five days have also been used. Caput medusae Esophagitis Gastric varices Mallory-Weiss ... octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind ...
Octreotide is a synthetic modifications of somatostatin with a longer half-life.[citation needed] OctreoScan, also called ... to detect larger lesions with tumor cells that are avid for octreotide.[citation needed] Somatostatin receptor imaging can now ... Placebo-controlled prospective randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic ... especially somatostatin analogs such as octreotide.[citation needed] Most gastrointestinal carcinoid tumors tend not to respond ...
Takeo C, Myojo S (2000). "Marked effect of octreotide acetate in a case of pancreatic pleural effusion". Curr Med Res Opin. 16 ...
211At-labeled octreotide Somatostatin receptor 211At-labeled monoclonal antibodies and fragments Various ...
"111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors". Journal of Nuclear Medicine. 41 (4 ... Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ...
... can often be treated with diazoxide or a somatostatin analog called octreotide. Diazoxide is given by mouth, octreotide by ...
"In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured ... Somatostatin receptor genes expression and effects of octreotide on orbital fibroblasts from Graves' ophthalmopathy]". Minerva ...
Hudson E, Lester J, Attanoos R, Linnane S, Byrne A (2006). "Successful treatment of bronchorrhea with octreotide in a patient ... epidermal growth factor receptor tyrosine kinase inhibitor indomethacin corticosteroids octreotide radiation therapy ...
Octreotide: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking octreotide,. *tell your doctor and pharmacist if you are allergic to octreotide, any other medications, or any of ... Octreotide may control your symptoms, but it will not cure your condition. Do not stop taking octreotide without talking to ... Octreotide comes as a capsule to take by mouth. It is usually taken twice daily on an empty stomach, at least 1 hour before or ...
Octreotide Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Continue to use octreotide injection even if you feel well. Do not stop using octreotide injection without talking to your ... Before using octreotide injection,. *tell your doctor and pharmacist if you are allergic to octreotide injection, any other ... Octreotide immediate-release injection is usually injected 2 to 4 times a day. Octreotide long-acting injection is usually ...
Octreotide is a type of medicine called a somatostatin analogue. It is similar to a naturally-occurring hormone in the body ... Sandostatin LAR is a long-acting depot injection that contains the active ingredient octreotide. ... Other medicines containing octreotide. *Sandostatin short-acting injection.. Octreotide injection is also available without a ... Sandostatin LAR (octreotide). Sandostatin LAR is a long-acting depot injection that contains the active ingredient octreotide. ...
Octreotide can also be used in the treatment of acromegaly, a disorder of excessive growth hormone (GH). Octreotide, being a ... Octreotide acetate was approved for use in the United States in 1988. In January 2020, approval of octreotide acetate in the ... "Octreotide". Drug Information Portal. U.S. National Library of Medicine. "Octreotide acetate". Drug Information Portal. U.S. ... Some studies reported alopecia in those who were treated by octreotide. Rats which were treated by octreotide experienced ...
Medical definition of octreotide: a long-acting synthetic analog of somatostatin that is a cyclic octapeptide, is administered ... Learn More about octreotide. Share octreotide Post the Definition of octreotide to Facebook Share the Definition of octreotide ... Comments on octreotide What made you want to look up octreotide? Please tell us where you read or heard it (including the quote ... Dictionary Entries near octreotide. octopamine octoploid octose octreotide ocular ocularist ocular micrometer ...
A list of US medications equivalent to Octreotide Acetate Omega is available on the Drugs.com website. ... Octreotide Acetate Omega is a medicine available in a number of countries worldwide. ... Ingredient matches for Octreotide Acetate Omega. Octreotide. Octreotide acetate (a derivative of Octreotide) is reported as an ... Octreotide Acetate Omega. Octreotide Acetate Omega may be available in the countries listed below. ...
Video Tag: Octreotide. SAGES Webinar : Preparing for the ABSITE-December 2017. Preparing for ABSITE Chair: Michael M. Awad, MD ... octreotide, oncologic outcomes, open aortic aneurysm repair, open inguinal hernia repair, outpatient, overtube, pain, pain ...
... an octreotide scan is a non-invasive nuclear medicine test used to evaluate the body for the presence of neuroendocrine tumor ... What is an Octreotide scan?. An octreotide scan, also known as somatostatin receptor scintigraphy, is a test used to check the ... How do I prepare for an octreotide scan?. If you are taking octreotide or somatostatin, you may need to stop the medication ... Obinutuzumab Octreotide Odomzo® Ofatumumab Olanzapine Oral / IM Olaparib Omacetaxine Mepesuccinate Oncaspar Oncovin® ...
A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body. Octreotide ... An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after ... An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize ... Octreotide scan entry in the public domain NCI Dictionary of Cancer Terms This article incorporates public domain material from ...
Professional guide for Octreotide. Includes: pharmacology, pharmacokinetics, contraindications, interactions, adverse reactions ... Although octreotide use is strongly advocated as a first-line therapy, indications and dosing for octreotide are not firmly ... continued octreotide for up to a maximum of 12 months; patients with stable disease continued octreotide and also received ... indications and dosing for octreotide are not firmly established (Glatstein 2012). Octreotide may reduce the incidence of ...
Octreotide and Graves ophthalmopathy and pretibial myxoedema.. BMJ 1992; 304 doi: https://doi.org/10.1136/bmj.304.6820.158 ( ...
How effective octreotide can be (for treatment and symptomatic relief) in the case of bowel obstruction due to cancer cells ... I have used octreotide alot in my practice. There is along acting form called sandostatin LAR by Novartis. This is a monthly ... Octreotide is one of the agents that can improve the quality of life of women with ovarian cancer. Mostly women who received ... How effective octreotide can be (for treatment and symptomatic relief) in the case of bowel obstruction due to cancer cells ...
Octreotide (Sandostatin®, Sandostatin LAR®) is an injectable medication used to treat the symptoms of carcinoid, neuroendocrine ... About: Octreotide (Sandostatin®, Sandostatin LAR®) Octreotide is a hormone that occurs naturally in the body. It is used to ... How to Take Octreotide. The short acting form of octreotide is given as a subcutaneous injection (injection under the skin) or ... Possible Side Effects of Octreotide. There are a number of things you can do to manage the side effects of Octreotide. Talk to ...
Octreotide Acetate (Sandostatin) hormone therapy side effects, how its given, how it works, precautions and self care tips for ... Other names: Octreotide acetate. Drug type: Octreotide is hormone drug that is used to treat some types of cancer. This ... Octreotide, in contrast, is very stable and, therefore, much longer acting. It is for this reason that octreotide is preferred ... Octreotide has two formulations. For purposes of clarity, trade names will be used for discussion. Sandostatin® is a short ...
octreotide 1 MG/ML Injectable Solution. SCD. 14. 312071. octreotide (as octreotide acetate) 1000 MCG/ML Injectable Solution. SY ... octreotide 0.2 MG/ML Injectable Solution. SCD. 17. 314152. octreotide (as octreotide acetate) 200 MCG/ML Injectable Solution. ... octreotide acetate (UNII: 75R0U2568I) (octreotide - UNII:RWM8CCW8GP) octreotide. 50 ug in 1 mL. ... octreotide acetate (UNII: 75R0U2568I) (octreotide - UNII:RWM8CCW8GP) octreotide. 100 ug in 1 mL. ...
Find the most comprehensive real-world treatment information on Octreotide at PatientsLikeMe. 17 patients with fibromyalgia, ... chronic obstructive pulmonary disease or bipolar I disorder currently take Octreotide. ... Currently taking Octreotide Duration. Patients. Percentage. This item is relevant to you: 10 years or more 1 * 100% ... Stopped taking Octreotide Duration. Patients. Percentage. This item is relevant to you: Less than 1 month 1 * 13% ...
OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP) OCTREOTIDE. 50 ug in 1 mL. ... OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP) OCTREOTIDE. 500 ug in 1 mL. ... OCTREOTIDE ACETATE (UNII: 75R0U2568I) (OCTREOTIDE - UNII:RWM8CCW8GP) OCTREOTIDE. 100 ug in 1 mL. ... OCTREOTIDE- octreotide acetate injection, solution. To receive this label RSS feed. Copy the URL below and paste it into your ...
Find patient medical information for Octreotide Acetate Injection on WebMD including its uses, side effects and safety, ... octreotide acetate 50 mcg/mL (1 mL) injection syringe. color. clear. shape. No data.. imprint. No data.. This medicine is a ... octreotide acetate 100 mcg/mL (1 mL) injection syringe. color. clear. shape. No data.. imprint. No data.. This medicine is a ... octreotide acetate 500 mcg/mL (1 mL) injection syringe. color. clear. shape. No data.. imprint. No data.. This medicine is a ...
Octreotide Acetate) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related ... Sandostatin is not compatible in Total Parenteral Nutrition (TPN) solutions because of the formation of a glycosyl octreotide ... Sandostatin® (octreotide acetate) Injection is available in 1 mL ampuls and 5-mL multi-dose vials as follows:. Ampuls. 50 mcg/ ... The elimination of octreotide from plasma had an apparent half-life of 1.7 to 1.9 hours compared with 1-3 minutes with the ...
Find the most comprehensive real-world treatment information on Octreotide at PatientsLikeMe. 16 patients with fibromyalgia, ... bipolar I disorder or psoriasis currently take Octreotide. ... Currently taking Octreotide Duration. Patients. This item is ... Stopped taking Octreotide Duration. Patients. This item is relevant to you: Less than 1 month 1 * 1 ... Why patients stopped taking Octreotide. Multiple reasons could be selected. Reason. Patients. This item is relevant to you: ...
Octreotide Oral Capsules) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related ... Each capsule contains 20 mg of octreotide (provided as octreotide acetate). Octreotide is present as a salt with 1.4 to 2.5 ... 20 mg octreotide acetate), and a single dose of subcutaneous Sandostatin IR (0.1 mg octreotide acetate). Peak octreotide levels ... Each capsule contains 20 mg octreotide, provided as octreotide acetate.. Storage And Handling. MYCAPSSA delayed-release 20 mg ...
Injectable; Injection; Octreotide 0.05 mg / ml*Injectable; Injection; Octreotide 0.1 mg / ml*Injectable; Injection; Octreotide ...
More information is available on octreotide including side effects, age restrictions, food interactions, whether the medicine ... Active ingredient: octreotide. The medicines below all contain the following active ingredient(s): octreotide. You can select a ...
Octreotide. Hypoglycaemia, injection site Staphylococcus epidermidis infection and endocarditis: 3 case reports ...
Octreotide is a man-made (synthetic) version of a naturally occurring hormone known as somatostatin. Octreotide is used to ... 02299437 OCTREOTIDE 100µG/ML Injection. 02299445 OCTREOTIDE 200µG/ML Injection. 02299453 OCTREOTIDE 500µG/ML Injection. ... Octreotide should not be used by anyone who is allergic to octreotide or to any of the ingredients of the medication. ... Octreotide is a man-made (synthetic) version of a naturally occurring hormone known as somatostatin. Octreotide is used to ...
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2). The safety and scientific validity of this ... Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3 ... Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with ... Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide ...
mean glucose level for the non-octreotide group is higher than the octreotide group. ... Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia. The safety and scientific validity of this study is the ... Octreotide is thought to block the elevated insulin levels that are a result of both the sulfonlyureas and dextrose. Recent ... Comparison of Octreotide and Standard Therapy vs. Standard Therapy Alone for the Treatment of Hypoglycemia in Patients Taking ...
Octreotide injection is also used to treat a condition called acromegaly, which is caused by too much growth hormone in the ... Octreotide injection is used to treat severe diarrhea and other symptoms that occur with certain intestinal tumors or ... Octreotide works by reducing the amount of growth hormone that is produced by the body. ...
... Clin Neurol Neurosurg. 1998 Mar;100(1):40-3. doi ... who experienced a significant clinical and visual improvement during short-term octreotide therapy, contrasting with the lack ...
The findings suggest that people who respond well to oral octreotide would be able to avoid the burden of injections if the ... An investigational oral form of octreotide was safe and effective for the treatment of acromegaly, a rare hormonal disorder, in ... Side Effects of Oral Octreotide Were Similar to Injectable Octreotide Approximately, 89% of patients experienced an adverse ... "Oral octreotide may not work for me, but it may help 10 other people," Ms Sisco said. "When you are dealing with a rare disease ...
  • You may be able to become pregnant during your treatment with octreotide even if you were not able to become pregnant before your treatment because you have acromegaly. (medlineplus.gov)
  • Octreotide long-acting injection is used to control acromegaly, carcinoid tumors, and VIP-omas in people who have been successfully treated with octreotide injection but prefer to receive injections less often. (medlineplus.gov)
  • If you have acromegaly and have been treated with radiation therapy, your doctor will probably tell you not to use octreotide immediate-release injection for 4 weeks every year or not to receive the octreotide long-acting injection for 8 weeks every year. (medlineplus.gov)
  • Octreotide is also used to treat acromegaly, which is a condition characterised by enlarged facial features, hands and feet. (netdoctor.co.uk)
  • Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma),[citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors (VIPomas). (wikipedia.org)
  • Octreotide can also be used in the treatment of acromegaly, a disorder of excessive growth hormone (GH). (wikipedia.org)
  • In June 2020, Mycapssa (octreotide) was approved for medical use in the United States with an indication for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. (wikipedia.org)
  • The Food and Drug Administration (FDA) has approved the usage of a salt form of this peptide, octreotide acetate, as an injectable depot formulation for the treatment of acromegaly, the treatment of diarrhea and flushing episodes associated with carcinoid syndrome, and treatment of diarrhea in patients with vasoactive intestinal peptide-secreting tumors (VIPomas). (medhelp.org)
  • Octreotide acetate substantially reduces growth hormone and/or IGF-I (somatomedin C) levels in patients with acromegaly. (nih.gov)
  • Octreotide is also used to treat a certain condition ( acromegaly ) that occurs when the body makes too much of a certain natural substance called growth hormone . (webmd.com)
  • Sandostatin® (octreotide acetate) is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection , pituitary irradiation , and bromocriptine mesylate at maximally tolerated doses. (rxlist.com)
  • Mycapssa (octreotide) is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. (rxlist.com)
  • Octreotide also reduces the amount of growth hormone in the body, and so it is also used to treat acromegaly , a condition associated with overgrowth of the hands, feet, and parts of the face. (medbroadcast.com)
  • Octreotide injection is also used to treat a condition called acromegaly, which is caused by too much growth hormone in the body. (mayoclinic.org)
  • An investigational oral form of octreotide was safe and effective for the treatment of acromegaly , a rare hormonal disorder, in a recent study. (endocrineweb.com)
  • The phase 3 trial was designed to see whether people with acromegaly were able to maintain a good response to treatment when switched from their injectable medications to oral octreotide. (endocrineweb.com)
  • For people who responded to oral octreotide, the severity and frequency of acromegaly symptoms improved, compared to when patients took injectable medications. (endocrineweb.com)
  • These side effects are similar to those for injectable octreotide or are consistent with symptoms of acromegaly. (endocrineweb.com)
  • Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. (endocrineweb.com)
  • An investigational oral formulation of octreotide was found to be safe and effective in the treatment of acromegaly in a phase 3 open-label study published online ahead of print in the Journal of Clinical Endocrinology & Metabolism . (endocrineweb.com)
  • The most common adverse events (AEs) reported were gastrointestinal (nausea, diarrhea and abdominal pain), neurological, and musculoskeletal, consistent with the known safety profile of octreotide and the disease burden of acromegaly. (endocrineweb.com)
  • Octreotide-MaxRx Injection is used to treat acromegaly. (nps.org.au)
  • In a recent phase 3 trial, oral octreotide capsules demonstrated sustained biochemical response up to 13 months in patients with acromegaly previously managed with somatostatin analog injections (ref). (centerwatch.com)
  • This will be a phase 3, randomized, open-label, active controlled, multicenter study to evaluate maintenance of response, safety and patient reported outcomes (PROs) in acromegaly patients treated with octreotide capsules and in patients treated with SOC parenteral SRLs, who previously tolerated and demonstrated biochemical control on both treatments. (centerwatch.com)
  • Patients whose acromegaly is been controlled biochemically on octreotide capsules at the end of the Run-in Phase will enter a 36-week open-label Randomized Controlled Treatment Phase, where they will be randomized to continue on octreotide capsules or switch back to their injectable SRL treatment (as received prior to Screening). (centerwatch.com)
  • Octreotide(Sandostatin) generic Sandostatin LAR is a synthetic octapeptide, prescribed for acromegaly. (medindia.net)
  • DP1038 (octreotide acetate for intranasal administration) is being developed via the 505(b)(2) regulatory pathway for the treatment of acromegaly and neuroendocrine tumors. (medindia.net)
  • What the FDA's complete response letter (CRL) for Mycapssa ( octreotide capsules) to treat adult patients with acromegaly might mean for the ongoing European study remained unclear, as Chiasma Inc. is "revisiting all priorities" and preparing for a post-review meeting with U.S. regulators, said CEO Mark Leuchtenberger. (bioworld.com)
  • SAN JOSE, Calif., Jan. 30, 2020 /PRNewswire/ -- Rani Therapeutics , the leader in oral biologics, has today announced positive results from the Phase I clinical study of its orally-delivered version of octreotide, Octreotide-RP, a drug used in the treatment of acromegaly and neuroendocrine tumors. (pharmiweb.com)
  • By providing an oral alternative like Octreotide-RP, Rani Therapeutics is making therapy easier and painless for patients, a welcome change for acromegaly and neuroendocrine tumor patients," said Dr. Shlomo Melmed, Executive Vice President of Academic Affairs, Dean of the Medical Faculty and Professor of Medicine at Cedars Sinai. (pharmiweb.com)
  • Octreotide has been widely used in the treatment of acromegaly. (ovid.com)
  • Swiss drugmaker Roche has struck a $595 million (£390 million) deal with US firm Chiasma for Octreolin (octreotide) tablets for treating acromegaly, a rare condition that causes excessive growth. (chemistryworld.com)
  • Octreotide is clinically used for the treatment of esophageal varices caused by portal hypertension, acromegaly, gastrointestinal bleeding including cirrhosis, esophageal varices bleeding, peptic ulcer bleeding and stress ulcer bleeding, pancreatic diseases including heavy acute pancreatitis, pancreatic trauma, or pancreatic fistula after surgery, and prevention of complications after pancreas surgery. (chemicalbook.com)
  • Currently approved octreotide products are used for the treatment of several serious disorders, including acromegaly and certain neuroendocrine tumours, and the market for immediate release liquid formulations is estimated to be in excess of $150 million. (fiercepharma.com)
  • Approximately half of patients with acromegaly do not respond to treatment with somatostatin receptor ligands such as octreotide LAR. (checkorphan.org)
  • Ultrasound guidance of IM injections may improve accuracy of placement of IM injections and increase drug levels, thereby improving efficacy of octreotide LAR for the treatment of acromegaly. (checkorphan.org)
  • The purpose of this study is to determine whether octreotide LAR drug levels differ if given by ultrasound-guided IM injection or by regular IM injection in patients with acromegaly. (checkorphan.org)
  • STUDY OBJECTIVE: To determine the efficacy of stepwise incremental doses, to compare twice- with thrice-daily administration of the same total daily dosage of the long-acting somatostatin analog SMS 201-995 (octreotide, Sandoz Australia, Sydney, Australia), and to evaluate the risk for cholelithiasis after long-term therapy for acromegaly. (garvan.org.au)
  • Octreotide is effective and can be considered as a first-line therapy in patients with acromegaly with mean pretherapy GH concentrations below 20 mIU/L. In patients with mean GH over 20 mIU/L, octreotide may be used as an adjuvant to surgery or radiotherapy. (garvan.org.au)
  • Midatech Pharma PLC (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products for rare diseases in oncology and immunotherapy, today announces interim data from the 'first-in-human' study of MTD201 Q-Octreotide, a sustained-release treatment for carcinoid cancer and acromegaly. (apnews.com)
  • Octreotide is a somatostatin analogue that is FDA approved for the treatment of acromegaly , severe diarrhea / flushing episodes associated with metastatic carcinoid tumors , profuse watery diarrhea associated with VIP-secreting tumors . (wikidoc.org)
  • OCTREOTIDE (ok TREE oh tide) is used to reduce blood levels of growth hormone in patients with a condition called acromegaly. (covenanthealth.com)
  • and other symptoms) in people who have been treated successfully with octreotide injection (Sandostatin) or lanreotide injection (Somatuline). (medlineplus.gov)
  • Octreotide injection is in a class of medications called octapeptides. (medlineplus.gov)
  • Octreotide comes as an immediate-release solution (liquid) for injection to be injected subcutaneously (under the skin) or intravenously (into a vein) Octreotide also comes as a long-acting injection to be injected into the muscles of the buttocks by a doctor or nurse. (medlineplus.gov)
  • Octreotide immediate-release injection is usually injected 2 to 4 times a day. (medlineplus.gov)
  • Octreotide long-acting injection is usually injected once every 4 weeks. (medlineplus.gov)
  • Inject octreotide immediate-release injection at around the same times every day. (medlineplus.gov)
  • Inject octreotide injection exactly as directed. (medlineplus.gov)
  • If you are not already being treated with octreotide injection, you will begin your treatment with immediate-release octreotide injection. (medlineplus.gov)
  • Octreotide immediate-release injection comes in vials, ampules, and dosing pens that contain cartridges of medication. (medlineplus.gov)
  • These instructions describe how to inject a dose of octreotide injection. (medlineplus.gov)
  • Sandostatin LAR is a long-acting depot injection that contains the active ingredient octreotide. (netdoctor.co.uk)
  • Sandostatin LAR is a long-acting depot injection of octreotide that is given into the muscle of the buttock (intragluteal) every four weeks by your doctor. (netdoctor.co.uk)
  • An IV is placed and an injection of octreotide with radioactive material attached to it (called "radiolabeled"), is given. (oncolink.org)
  • About 4 hours after the injection, the patient will undergo a scan to look for cells that have taken up the octreotide. (oncolink.org)
  • Limitations of use: The effects of octreotide (injection solution and LAR depot suspension) on tumor size, rate of growth, and development of metastases in patients with carcinoid syndrome and VIPomas have not been determined. (drugs.com)
  • The short acting form of octreotide is given as a subcutaneous injection (injection under the skin) or in an intravenous (IV) form. (oncolink.org)
  • Octreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution with a pH range 3.9 to 4.5 for administration by deep subcutaneous (intrafat) or intravenous injection. (nih.gov)
  • Octreotide acetate injection is available as: sterile 1 mL single dose vials in 3 strengths, containing 50, 100 or 500 mcg octreotide (as acetate), and sterile 5 mL multi-dose vials in 2 strengths, containing 200 and 1,000 mcg per mL of octreotide (as acetate). (nih.gov)
  • After subcutaneous injection, octreotide is absorbed rapidly and completely from the injection site. (nih.gov)
  • Octreotide Acetate Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. (nih.gov)
  • Octreotide injection is used to treat severe diarrhea and other symptoms that occur with certain intestinal tumors or metastatic carcinoid tumors (tumors that has already spread in the body). (mayoclinic.org)
  • I know people who are on the long-acting octreotide and, at the end of the monthly cycle, have to supplement it with short-acting octreotide injection 3 times a day," she explained. (endocrineweb.com)
  • The actual octreotide molecule-the active drug that is present in the capsule-is identical to the molecule that is present in the injection. (endocrineweb.com)
  • Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms). (nih.gov)
  • Octreotide may be administered as an injection under the skin (subcutaneous), or as an injection into a muscle (intramuscular) and the dose depends on several factors, including the condition being treated, the particular regimen being used, and the overall health of the patient. (unm.edu)
  • Please read this leaflet carefully before you start using Octreotide MaxRx Solution for injection. (nps.org.au)
  • This leaflet answers some common questions about Octreotide-MaxRx Injection. (nps.org.au)
  • Your doctor has weighed the risks of you using Octreotide-MaxRx Injection against the benefits they expect it will have for you. (nps.org.au)
  • By blocking the excess growth hormone, Octreotide-MaxRx Injection can relieve many of these symptoms. (nps.org.au)
  • Octreotide-MaxRx Injection is used to relieve symptoms of certain types of cancer such as carcinoid syndrome and VIPoma. (nps.org.au)
  • By blocking hormones that are over-produced in these conditions, Octreotide-MaxRx Injection can relieve symptoms such as flushing of the skin and severe diarrhoea. (nps.org.au)
  • About the Phase 1 Trial The Phase 1 trial was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DP1038, a novel formulation of octreotide acetate for intranasal administration, compared to subcutaneous Sandostatin (octreotide acetate) Injection in healthy volunteers. (medindia.net)
  • Your search for octreotide injection (generic equivalent to sandostatin) (5 x 1ml) did not match any products. (jandrugs.com)
  • Of the 58 participants, 52 were treated with Octreotide-RP, while a control group of 6 participants was given an intravenous injection of an identical dose of octreotide. (pharmiweb.com)
  • Current octreotide delivery methods compel patients to choose between painful injections and living with debilitating symptoms especially occurring at the end of injection cycles. (pharmiweb.com)
  • The active compound, octreotide , is already commercially available as an injection, marketed by Novartis under the name Sandostatin. (chemistryworld.com)
  • Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that it has appointed Albany Molecular Research (Glasgow) Limited (AMRI) to manufacture the company's novel solid dose injection (SDI) formulation of octreotide, for use in a human bioequivalence study to be conducted in Q4 2015. (fiercepharma.com)
  • Portal hypertensive rats were allocated into one of four groups (eight rats in each group): vehicle group, octreotide group (100 μg/kg via subcutaneous injection every 12 h), isosorbide dinitrate group (5 mg/kg via gastric gavage every 12 h) and combined treatment group. (portlandpress.com)
  • 50% hormone level decrease after octreotide s.c. injection (octreotide test) (OT). (enets.org)
  • Description: Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months. (checkorphan.org)
  • On day 1 subjects received 100 μg of octreotide or placebo subcutaneously, three times daily and on day 2, one hour after the fourth injection, gastric emptying, postprandial cholecystokinin (CCK) release, and mouth to caecum transit time (MCTT) were measured. (bmj.com)
  • The 2 somatostatin analogs currently recommended by the National Comprehensive Cancer Network for the treatment of gastrointestinal (GI) neuroendocrine tumors (NETs) include octreotide long-acting release (Sandostatin LAR) for injectable suspension and lanreotide (Somatuline Depot) injection for subcutaneous use. (ahdbonline.com)
  • Appropriate studies have not been performed on the relationship of age to the effects of the short-acting form of octreotide injection in the pediatric population. (allinahealth.org)
  • Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of the long-acting form of octreotide injection in children 6 to 17 years of age. (allinahealth.org)
  • Although appropriate studies on the relationship of age to the effects of octreotide have not been performed in the geriatric population, geriatric-specific problems are not expected to limit the usefulness of octreotide injection in the elderly. (allinahealth.org)
  • However, elderly patients are more likely to have age-related kidney, liver, or heart problems, which may require caution and an adjustment in the dose for patients receiving octreotide injection. (allinahealth.org)
  • Octreotide injection, 50 mcg/ml (1ml) Inj. (gouv.qc.ca)
  • Octreotide injection, 100 mcg/ml (1 ml) Inj. (gouv.qc.ca)
  • Octreotide injection, 500 mcg/ml (1 ml) Inj. (gouv.qc.ca)
  • Patients not currently receiving octreotide acetate should begin therapy with Sandostatin Injection given subcutaneously in an initial dose of 50 mcg three times daily which may be titrated. (wikidoc.org)
  • Patients should be maintained on Sandostatin Injection subcutaneous for at least 2 weeks to determine tolerance to octreotide. (wikidoc.org)
  • Patients not currently receiving octreotide acetate should begin therapy with Sandostatin Injection given subcutaneously. (wikidoc.org)
  • Thereafter, patients who are considered "responders" to octreotide acetate and who tolerate the drug may be switched to Sandostatin LAR Depot in the dosage regimen as described below (Patients Currently Receiving Sandostatin Injection). (wikidoc.org)
  • Because of the need for serum octreotide to reach therapeutically effective levels following initial injection of Sandostatin LAR Depot, carcinoid tumor and VIPoma patients should continue to receive Sandostatin Injection subcutaneously for at least 2 weeks in the same dosage they were taking before the switch. (wikidoc.org)
  • The long-acting formulation, Sandostatin LAR, is octreotide contained in "microspheres", which allow the drug to be slowly released into the body over a 4-week period. (oncolink.org)
  • The side effects of octreotide and their severity depend on how much of the drug is given and which preparation (Sandostatin ® or Sandostatin LAR ® ) is given. (chemocare.com)
  • Sandostatin LAR Depot is available as: sterile 6-mL vials in 3 strengths delivering 10 mg, 20 mg, or 30 mg octreotide-free peptide. (rxlist.com)
  • To verify that long-acting somatostatin analog octreotide (Sandostatin LAR) depot will extend median survival from 5 months to 8.75 months in patients with locally advanced or metastatic hepatocellular carcinoma with a CLIP score of 3 or more. (knowcancer.com)
  • The findings suggest that people who respond well to oral octreotide would be able to avoid the burden of injections if the oral form is approved by the U.S. Food and Drug Administration. (endocrineweb.com)
  • After 7 months of treatment at a fixed dose, 65% of participants were considered well controlled on oral octreotide. (endocrineweb.com)
  • In addition, 86% who completed the fixed-dose phase chose to participate in a voluntary 6-month extension phase in which they continued using oral octreotide. (endocrineweb.com)
  • Notably, 85% of the patients who were well controlled on oral octreotide in the first phase of the study maintained this response up to 13 months in the extension phase. (endocrineweb.com)
  • Oral octreotide may not work for me, but it may help 10 other people," Ms Sisco said. (endocrineweb.com)
  • The most common adverse events reported with oral octreotide in this study were gastrointestinal, neurological, and musculoskeletal. (endocrineweb.com)
  • At the end of the 6-month extension phase, 62% of participants achieved the primary endpoint on oral octreotide. (endocrineweb.com)
  • The purpose of this study is to compare the efficacy safety and patient reported outcomes between oral octreotide capsules and injectable somatostatin analogs. (centerwatch.com)
  • After Basel, Switzerland-based Roche AG quietly ended its deal with Chiasma for oral octreotide in 2014, Chiasma decided to forge ahead without a partner. (bioworld.com)
  • In addition to oral octreotide, Rani has a pipeline of drugs for the treatment of diabetes, osteoporosis, and rheumatoid arthritis, among other diseases. (pharmiweb.com)
  • Standard treatment plus 75 micrograms octreotide subcutaneously. (clinicaltrials.gov)
  • Patients receive short-acting octreotide subcutaneously three times daily on days 1-21 OR days 1-28. (knowcancer.com)
  • Subsequently, octreotide (50 micrograms, three times daily) was administered subcutaneously for 7 days. (diabetesjournals.org)
  • Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. (knowcancer.com)
  • The antiproliferative effect of Octreotide on metastatic NET is still poorly understood and hasn't been finally evaluated in studies. (egms.de)
  • Methods: Using membrane invasion culture system alone or coated with matrigel, we observed the effect of octreotide on blocking migration and invasion of gastric carcinoma cells. (paper.edu.cn)
  • Aims -To assess the effect of octreotide, at the clinical dosage used after pancreatic surgery, on gastric emptying in healthy volunteers. (bmj.com)
  • The effect of octreotide on gastric motility and emptying rate in patients after pancreatic surgery is unknown. (bmj.com)
  • There is thus only an acute effect of octreotide on the perfusion of liver metastases. (eur.nl)
  • There are a number of things you can do to manage the side effects of Octreotide. (oncolink.org)
  • OBJECTIVE To evaluate the inhibitory effects of octreotide and diazoxide on insulin secretion in patients with type 1 diabetes and measurable levels of circulating C-peptide. (diabetesjournals.org)
  • Differential effects of octreotide on endocrine secretions such as growth hormone (GH) and insulin in healthy volunteers, as well as variable efficacy in the treatment of endocrine tumours, may relate to the distribution of somatostatin receptor subtypes. (ovid.com)
  • The wide spectrum of effects of octreotide in humans accounts for adverse effects seen during long term treatment, primarily cholelithiasis. (ovid.com)
  • The aim of the present study was to verify the effects of octreotide on hepatic glycogenesis in rats with HFD‑induced obesity. (spandidos-publications.com)
  • We have investigated the acute and sustained hemodynamic effects of octreotide on hepatic metastases of midgut carcinoids using contrast-enhanced dynamic magnetic resonance imaging (MRI). (eur.nl)
  • If you miss an appointment to receive octreotide, contact your doctor as soon as possible to reschedule your appointment. (medbroadcast.com)
  • Following the completion of the core study (Screening, Run-in and RCT phases), eligible patients will be offered to enter the Study Extension phase and receive octreotide capsules until product marketing or study termination. (centerwatch.com)
  • Patients then receive octreotide alone for 6-8 courses. (knowcancer.com)
  • Patients with documented recurrent tumor progression ineligible for further surgery/radiotherapy were eligible to receive octreotide (30 mg/d, day 1) and everolimus (10 mg/d, days 1-28). (aacrjournals.org)
  • Octreotide decreases the production of the growth hormone and so treats the symptoms of the condition, however, again it does not cure the tumour. (netdoctor.co.uk)
  • Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. (wikipedia.org)
  • Octreotide provides more potent inhibition of growth hormone, glucagon, and insulin as compared to endogenous somatostatin. (drugs.com)
  • Octreotide works by decreasing the amount of growth hormone to normal levels. (webmd.com)
  • Octreotide works by reducing the amount of growth hormone that is produced by the body. (mayoclinic.org)
  • Subjects were given a GHRH-arginine challenge, a standard test to stimulate growth hormone release, followed by administration of DP1038 or subcutaneous octreotide acetate. (medindia.net)
  • Therapeutic octreotide concentrations were achieved, and growth hormone levels were suppressed in this trial by an average of 25%, comparable with SLAR. (apnews.com)
  • Octreotide is a synthetic analogue of somatostatin which acts by suppressing basal and stimulated secretion of growth hormone (GH). (drugsupdate.com)
  • Octreotide acetate alters the balance between the counter-regulatory hormones, insulin, glucagon and growth hormone, which may result in hypoglycemia or hyperglycemia. (drugsupdate.com)
  • Raw Octreotide powder is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. (phcoker.com)
  • In unresectable metastatic liver lesions positive for somatostatin receptors repeated, transhepatic high doses of 111 In-DTPA-Phe 1 -octreotide show an effective therapeutic outcome. (springer.com)
  • This trial achieved all its endpoints confirming that therapeutic doses of octreotide administered via intranasal delivery are well tolerated and supports our goal of providing patients with the first viable non-invasive option for managing their disease," said Joel Martin , Ph.D., President and Chief Executive Officer of Dauntless Pharmaceuticals. (medindia.net)
  • Therefore, octreotide may be regarded as a novel therapeutic strategy for HFD‑induced obesity and obesity‑associated metabolic disorders. (spandidos-publications.com)
  • The goal of this research is to cyclize octreotide analogues with ⁹⁹[supersript-m]Tc and ¹⁸⁶/¹⁸⁸Re radiometals to be used as diagnostic and therapeutic agents for neuroendocrine tumors, respectively. (umsystem.edu)
  • Octreotide can also be labeled with a variety of radionuclides, such as yttrium-90 or lutetium-177, to enable peptide receptor radionuclide therapy (PRRT) for the treatment of unresectable neuroendocrine tumours. (wikipedia.org)
  • By virtue of these pharmacological actions, octreotide acetate has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). (nih.gov)
  • Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (e.g., carcinoid tumors , vasoactive intestinal peptide tumors) that are found usually in the intestines and pancreas . (webmd.com)
  • Octreotide is FDA approved for the management of diarrhea and flushing, as part of carcinoid syndrome caused by carcinoid tumor or vasoactive intestinal peptide (VIP) secreting adenomas. (unm.edu)
  • About DP1038 Octreotide is a synthetic peptide analog of naturally occurring somatostatin, with similar pharmacological effects but longer duration of action. (medindia.net)
  • The purpose of the present study was to characterize the in vivo release kinetics of octreotide acetate from microsphere formulations designed to minimize peptide acylation and improve drug stability. (springer.com)
  • 12 13 Octreotide inhibits secretion of gastrointestinal hormones such as cholecystokinin (CCK), gastrin, pancreatic polypeptide, motilin, secretin, glucose dependent insulinotropic peptide (GIP), vasoactive intestinal polypeptide (VIP), insulin, and glucagon, and impairs gastric and pancreatic secretion and gall bladder motility. (bmj.com)
  • Before starting octreotide treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc. (chemocare.com)
  • Smith S, Anthony L, Roberts LJ, Oates JA, Pincus T. Resolution of Musculoskeletal Symptoms in the Carcinoid Syndrome after Treatment with the Somatostatin Analog Octreotide. (annals.org)
  • Purpose: To report on the efficacy of the somatostatin analog octreotide long-acting repeatable (LAR), in the treatment of uveitic chronic macular edema (CME). (eur.nl)
  • People with diabetes mellitus might need less insulin or oral antidiabetics when treated with octreotide, as it inhibits glucagon secretion more strongly and for a longer time span than insulin secretion. (wikipedia.org)
  • Single doses of octreotide acetate have been shown to inhibit gallbladder contractility and to decrease bile secretion in normal volunteers. (nih.gov)
  • Octreotide acetate suppresses secretion of thyroid stimulating hormone (TSH). (nih.gov)
  • Since this scintigraphy demonstrated the presence of somatostatin receptors, empiric treatment with the somatostatin analogue octreotide was initiated in an attempt to stabilize catecholamine secretion prior to attempted surgical resection. (spandidos-publications.com)
  • Treatment of pain in chronic pancreatitis by inhibition of pancreatic secretion with octreotide. (bmj.com)
  • Octreotide acetate also suppresses secretion of thyroid stimulating hormone, which may result in hypothyroidism. (drugsupdate.com)
  • Octreotide, being a somatostatin analog, inhibits the release of GH from the pituitary gland through a process normally involved in negative feedback. (wikipedia.org)
  • MYCAPSSA delayed release capsules contain octreotide acetate, a somatostatin analog. (rxlist.com)
  • Octreotide is a somatostatin analog that is known to suppress numerous hormones including insulin. (clinicaltrials.gov)
  • Octreotide (Sandostatin), a somatostatin analog, has a wide range of uses in the management of cancer patients. (cancernetwork.com)
  • Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. (worldbid.com)
  • The acute symptoms are inhibited by the long-acting octapeptide analog of somatostatin, octreotide (SMS-201-995) (2). (annals.org)
  • Additional data may be necessary to further define the role of octreotide in this condition. (drugs.com)
  • In an established guinea pig model, the role of octreotide in lymphatic function was examined. (lymphedemapeople.com)
  • Recent case reports and one prospective study in healthy volunteers have demonstrated the safety and efficacy of octreotide administration for the treatment of sulfonylurea induced hypoglycemia. (clinicaltrials.gov)
  • The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. (diabetesjournals.org)
  • To evaluate the efficacy of octreotide in the treatment of pituitary thyroid-stimulating hormone (TSH)-secreting adenomas. (annals.org)
  • Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1. (clinicaltrials.gov)
  • Based largely on the results of these studies some experts in field of toxicology have argued that administration of octreotide be standard therapy for all patients with recurrent hypoglycemic episodes who are known to be taking sulfonylureas. (clinicaltrials.gov)
  • A Sub-study, in selected sites, would allow patients with in-adequate biochemical control on octreotide capsules during the Run-in Phase to enter a Combination phase and receive co-administration of octreotide capsules with cabergoline tablets for a total of 36 weeks. (centerwatch.com)
  • We speculate that liver cirrhosis can be a cause of intestinal lymphangiectasia and administration of octreotide should be considered for patients with intestinal lymphangiectasia whose clinical and biochemical abnormalities do not respond to a low-fat diet. (lymphedemapeople.com)
  • The present study was undertaken to evaluate the effect of long-term administration of octreotide and isosorbide dinitrate on haemodynamics in rats with portal vein stenosis. (portlandpress.com)
  • CONCLUSION: Thrice-daily was more effective than twice-daily administration of octreotide, and dose increments above 100 micrograms thrice daily did not confer additional benefit. (garvan.org.au)
  • 0.05), whereas octreotide had no such effect. (diabetesjournals.org)
  • 0.05), octreotide being the more potent in this respect. (diabetesjournals.org)
  • MEASUREMENTS AND MAIN RESULTS: Octreotide, 100 micrograms administered twice or thrice daily, significantly reduced mean 12-hour and nadir GH (P less than 0.01), IGF-1 (P less than 0.05), and hand volume (P less than 0.05). (garvan.org.au)
  • An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after treatment. (wikipedia.org)
  • The aim of this study is to evaluate the effectiveness of 111 In-DTPA-Phe 1 -octreotide infusions after selective catheterization of the hepatic artery in inoperable metastasised liver, sst 2 receptor-positive neuroendocrine tumours due to the effect of 111 In Auger electron emission, minimising in parallel the toxicity of non-target tissue. (springer.com)
  • Kaltsas GA, Stefanidou Z, Papadogias D, Grossmann A. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogue octreotide. (springer.com)
  • Octreotide is currently only approved as an injectable formulation. (endocrineweb.com)
  • Injectable somatostatin analogs (including octreotide) typically are given once a month. (endocrineweb.com)
  • Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. (centerwatch.com)
  • Octreotide is the acetate salt of a cyclic octapeptide. (rxlist.com)
  • Octreotide belongs to digestive system drugs, which is an artificially synthetic cyclic octapeptide compound, and is a homolog of natural somatostatin. (chemicalbook.com)
  • A unique optimization of a Waters system for bioanalysis, from sample preparation to UPLC chromatography to tandem quadrupole MS, enables the determination and quantification of octreotide, a cyclic octapeptide that is used for treating cancer patients, at the 5 pg/mL level. (selectscience.net)
  • In Part 1 of the study, each of 12 subjects received three doses of DP1038 plus 100 micrograms of subcutaneous octreotide acetate in a randomized 4 x 4 Latin square design. (medindia.net)
  • In Part 2 of the study, a single dose of DP1038, which was selected to exhibit a similar pharmacokinetic profile to subcutaneous octreotide acetate, was evaluated in 20 subjects in a cross-over design to compare the pharmacodynamic effect to 100 micrograms of subcutaneous octreotide acetate. (medindia.net)
  • INTERVENTIONS: Eight patients (group 1) were treated with 100, 250, and 500 micrograms twice daily of octreotide, then switched to 333 micrograms three times daily, whereas 11 patients (group 2) were treated with 100, 200, 300, and 500 micrograms three times daily. (garvan.org.au)
  • This study investigates whether octreotide prevents the increases in hepatic flow and portal pressure that follow the ingestion of a meal in patients with cirrhosis. (nih.gov)
  • In conclusion, in patients with cirrhosis and portal hypertension, octreotide prevents the postprandial increase in hepatic blood flow, and consequently also in portal pressure. (nih.gov)
  • Hepatic metabolism of octreotide is extensive (30 to 40%) and about 11 to 20% of the dose is excreted unchanged in the urine. (ovid.com)
  • However, whether octreotide affects hepatic glycogenesis is unknown. (spandidos-publications.com)
  • In conclusion, the results indicate that octreotide improved hepatic glycogenesis and decreased FPG concentration in rats with HFD‑induced obesity. (spandidos-publications.com)
  • This was afrank, interactive forum reviewing new data on octreotide and the long-actingrelease (LAR) formulation, octreotide LAR depot, to determine its future inresearch. (cancernetwork.com)
  • on the development of specialty therapeutics, today announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration. (medindia.net)
  • David Stevens, Senior Director and Site Head of AMRI Glasgow, commented, 'AMRI is thrilled to work with Glide on the GMP manufacture of their octreotide formulation. (fiercepharma.com)
  • This study will assess the pharmacokinetic profile, safety and tolerability of an octreotide extended long-acting formulation after a single dose in humans. (bioportfolio.com)
  • Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. (clinicaltrials.gov)
  • Patients receive oral vatalanib once daily on days 1- 28 and octreotide* intramuscularly or IV on day 1. (clinicaltrials.gov)
  • Comets E, Mentre F, Kawai R, Nimmerfall F, Marbach P, Vonderscher J. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. (springer.com)
  • Cardiac conduction abnormalities have also occurred during treatment with Octreotide acetate. (drugsupdate.com)
  • Open Label - Patients who had progressive disease in this arm, can move to the open label Everolimus + depot octreotide by choice. (clinicaltrials.gov)
  • Scott Wadler and Babu Zachariah discuss potential researchavenues with octreotide LAR depot in the field of therapy-induced diarrhea. (cancernetwork.com)
  • Henotes the value of octreotide in the treatment of National Cancer Institute(NCI) Common Toxicity Criteria grade 3 and 4 diarrheas but elaborates on theemerging role of prophylactic octreotide (particularly the use and research onoctreotide LAR depot). (cancernetwork.com)
  • He reports on two small studies thatdemonstrated potential benefit of therapy with octreotide but emphasizes andoutlines two cooperative group studies (by the Radiation Therapy Oncology Groupand the North Central Cancer Treatment Group) that would systematically evaluatethe value of prophylactic octreotide LAR depot. (cancernetwork.com)
  • medical citation needed] Octreotide can reduce the intestinal reabsorption of ciclosporin, possibly making it necessary to increase the dose. (wikipedia.org)
  • Octreotide seems to work by reducing gastric and intestinal secretions. (medhelp.org)
  • Octreotide in intestinal lymphangiectasia: lack of a clinical response and failure to alter lymphatic function in a guinea pig model. (lymphedemapeople.com)
  • A small number of recent reports advocate the use of octreotide in intestinal lymphangiectasia. (lymphedemapeople.com)
  • although octreotide can alter splanchnic blood flow and intestinal motility, its actions on lymphatic function has never been investigated. (lymphedemapeople.com)
  • A case of a patient with intestinal lymphangiectasia who required a shunt procedure after failing medium chain triglycerides and octreotide therapy is presented. (lymphedemapeople.com)
  • During the management of this case, all existing literature on intestinal lymphangiectasia and all the known actions of octreotide were reviewed. (lymphedemapeople.com)
  • Because some of the case reports suggested that octreotide may improve the clinical course of intestinal lymphangiectasia by altering lymphatic function, a series of experiments were undertaken to assess this. (lymphedemapeople.com)
  • Primary intestinal lymphangiectasia successfully treated with octreotide. (lymphedemapeople.com)
  • Octreotide has also been used off-label for the treatment of severe, refractory diarrhea from other causes. (medhelp.org)
  • By decreasing watery diarrhea , octreotide helps to reduce the loss of body fluids and minerals . (webmd.com)
  • Octreotide may help control symptoms, such as diarrhea, caused by the tumor. (clinicaltrials.gov)
  • Octreotide mimics natural somatostatin to control the overproduction of certain hormones and to control symptoms such as diarrhea or flushing in patients with a carcinoid tumor or VIP. (unm.edu)
  • Octreotide was originally used as a opiod antagonist and is still used off label as a second/third line therapy for diarrhea from opiod withdrawal because of antidiarrheal properties. (wikem.org)
  • An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. (wikipedia.org)
  • An octreotide scan, also known as somatostatin receptor scintigraphy, is a test used to check the body for the presence of neuroendocrine tumor cells. (oncolink.org)
  • Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. (springer.com)
  • Internalization of radiolabelled [DTPA°]octreotide and [DOTA°, Tyr 3 ]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. (springer.com)
  • Octreotide may control your symptoms, but it will not cure your condition. (medlineplus.gov)
  • If you stop taking octreotide, your symptoms may return. (medlineplus.gov)
  • Octreotide only relieves the symptoms of these hormone-producing tumours, it does not cure the tumour. (netdoctor.co.uk)
  • Octreotide works to reduce the production of these hormones and thereby decrease the symptoms. (oncolink.org)
  • We describe three patients with the carcinoid syndrome in whom treatment with octreotide was followed by resolution of their musculoskeletal symptoms. (annals.org)
  • A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. (springer.com)
  • Clinical experience suggests the benefit of octreotide in preventing carcinoid crisis prior to invasive procedures in patients with neuroendocrine tumors [Oberg 2004] . (drugs.com)
  • We report the case of a 54-year-old female patient affected by a suspected pituitary macroadenoma with severe visual field defects, who experienced a significant clinical and visual improvement during short-term octreotide therapy, contrasting with the lack of neuroradiological evidence for tumor shrinkage. (nih.gov)
  • The Phase I clinical study of Octreotide-RP was conducted in Australia with 58 healthy adult volunteers. (pharmiweb.com)
  • The human results with octreotide are compelling and demonstrate the safety and efficacy of the RaniPill™, a major milestone for Rani but also a first for the industry," added Dennis Ausiello, M.D., Physician-in-Chief, Emeritus at Massachusetts General Hospital and Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School, and Rani Therapeutics board member. (pharmiweb.com)
  • Under the terms of the manufacturing agreement, AMRI will install the clinical production line developed by Glide into its GMP facility, and will produce sterile octreotide solid doses for clinical study. (fiercepharma.com)
  • In conclusion, in this case, octreotide failed to induce a clinical response and laboratory studies showed that octreotide did not alter lymphatic function. (lymphedemapeople.com)
  • Thus, the mechanisms by which octreotide induced clinical responses in the cases reported elsewhere in the literature remain unclear, but the present study suggests that it does not appear to act via increasing lymphatic pumping. (lymphedemapeople.com)
  • Octreotide administered at the clinical dosage for pancreatic surgery accelerates gastric emptying, mainly by shortening the lag time. (bmj.com)
  • Clinical pharmacokinetics of octreotide. (wikem.org)
  • Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. (bioportfolio.com)
  • The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide. (clinicaltrials.gov)
  • To estimate the costs to payers associated with 30-mg octreotide LAR and 120-mg lanreotide treatment among patients with metastatic GI-NETs. (ahdbonline.com)
  • Over a 5-year horizon, the costs of adverse events and administration accounted for 0.72% of the total cost for octreotide LAR and 0.51% of the total cost for lanreotide. (ahdbonline.com)
  • For the management of metastatic GI-NETs, the cost to payers of treatment with 30-mg octreotide LAR is considerably lower than with 120-mg lanreotide over 1-, 3-, and 5-year horizons. (ahdbonline.com)
  • Seven patients with the carcinoid syndrome and metastasized midgut carcinoid tumors underwent functional dynamic multi-phase gadolinium-enhanced MRI of selected liver metastases at baseline and 60 min after the subcutaneous (s.c.) administration of 100 μg octreotide, and also after 3 months with three times daily (t.i.d.) 100 μg octreotide s.c. (eur.nl)
  • Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors. (wikipedia.org)
  • Background -Octreotide is used in many centres to prevent complications after pancreatic surgery. (bmj.com)
  • 5-7 A number of recent randomised, placebo controlled multicentre trials showed that octreotide could reduce postoperative complications when administered to patients undergoing pancreatic surgery. (bmj.com)
  • 8-11 Although mortality was not affected in these studies, perioperative treatment with octreotide seems to be indicated in pancreatic surgery. (bmj.com)
  • Octreotide mimics the action of natural sandostatin and so decreases the production of these types of hormones. (netdoctor.co.uk)
  • Diazoxide inhibits hormonal release directly on the beta-cells, whereas octreotide exerts its effect indirectly, presumably by multiple actions on insulin sensitivity and insulin-releasing hormones. (diabetesjournals.org)
  • Octreotide helps in management of the fistula by reducing gastrointestinal secretions and inhibiting gastrointestinal motility, thus controlling and reducing its output. (wikipedia.org)
  • The octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. (rxlist.com)
  • Short-acting octreotide is injected under the skin ( subcutaneous ) of the hip, thigh, or abdomen 2 to 4 times daily. (medbroadcast.com)
  • The duration of action of octreotide acetate is variable but extends up to 12 hours depending upon the type of tumor. (nih.gov)
  • Antifibrotic action of octreotide has been reported in pulmonary fibrosis. (bioportfolio.com)
  • Results from the study indicate that MTD201 produces a safe and effective sustained-release profile of octreotide, supporting a once-monthly treatment interval, as is indicated for SLAR. (apnews.com)
  • The Phase I study successfully achieved both its primary and secondary endpoints, demonstrating the safety and tolerability of Octreotide-RP, the RaniPill™ loaded with octreotide, and high oral bioavailability of the biologic drug. (pharmiweb.com)
  • CONCLUSIONS: Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery. (diabetesjournals.org)
  • These results also suggest that octreotide, a molecule with different signalling pathways, was able as doxorubicin to generate a p53 breakdown product. (portlandpress.com)
  • Nude mice implanted orthotopically with SGC-7901 human stomach carcinoma were given injections of octreotide for 8 weeks. (paper.edu.cn)
  • Last week i stopped taking Cabergoline and started on daily injections of Octreotide. (dickymoo.com)
  • Octreotide is also used to treat thyrotrophic adenomas, which are a different type of tumour affecting the pituitary gland. (netdoctor.co.uk)
  • Octreotide is used when levels of TSH still remain too high following surgery or radiotherapy to treat the pituitary tumour, in the interim period until radiotherapy becomes effective, or in people for whom surgery is inappropriate. (netdoctor.co.uk)
  • In a minority of patients complete resistance to octreotide was observed and was not always related to the absence of somatostatin receptors in the tumour. (ovid.com)
  • Beside the symptomatic treatment a number of cases of partial tumour regression with octreotide administered with or without other treatment modalities have been reported in the literature [ Ref. 1] . (egms.de)
  • The chemotherapeutic drug doxorubicin and the anti-proliferative long-acting somatostatin analogue octreotide, both used in cancer treatment, have been shown to increase the expression of the p53 tumour suppressor protein. (portlandpress.com)
  • Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-dPhe(1)-Tyr(3)-octreotide. (eurekamag.com)
  • Octreotide is thought to block the elevated insulin levels that are a result of both the sulfonlyureas and dextrose. (clinicaltrials.gov)
  • Octreotide blunted the postprandial increase in serum insulin and glucagon levels observed in the placebo group. (nih.gov)
  • Octreotide acts by inhibiting the release of insulin from the pancreas. (gouv.qc.ca)
  • Octreotide is in a class of medication called somatostatin analogs, which currently are only available for use as injections. (endocrineweb.com)